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The endoplasmic reticulum (ER) exists as an elaborated network of flat sheets and 
cylindrical tubules. ER network interacts with several other organelles, including 
mitochondria to play a vital role in membrane dynamics and other functions. However, 
the impact of ER-mitochondrial interactions on apoptosis is poorly understood. Cancer 
cells acquire resistance to anti-cancer agents through different mechanisms, including 
failure to undergo apoptosis. Therefore, better understanding of ER-mitochondrial 
communications and their impact on apoptosis could unravel mechanisms of drug 
resistance. We have previously observed a reversible reorganisation of ER membranes 
in cells exposed to several pharmaceutical agents. Hence, we conducted this study 
using ER membrane reorganisation as a tool to explore ER-mitochondrial 
communication and how it impacts mitochondrial-mediated apoptosis.  This thesis is 
divided into three results chapters. 
In the first results chapter, using apogossypol as a prototype tool compound, it 
is shown that ER membrane reorganisation occurs at the level of ER tubules but does 
not involve ER sheets. Moreover, further characterisation of the subcellular 
localisation of reorganised membranes reveal that other organelles, such as 
mitochondria, lysosomes, Golgi complex were not involved in ER membrane 
reorganisation. Next, the effect of ER membrane reorganisation with respect to 
mitochondrial membrane dynamics and apoptosis was studied. The results indicate 
that ER membrane reorganisation prevents DRP-1-mediated mitochondrial fission as 




In the next results chapter, the objective was to examine the impact of ER 
membrane reorganisation modulators on apoptosis. Inhibitors of dihydroorotate 
dehydrogenase (DHODH), such as teriflunomide and leflunomide, not only prevent 
ER membrane reorganisation, but also antagonise the protective effects of the 
reorganised ER membranes against BH3 mimetic-mediated apoptosis. Since DHODH 
inhibitors antagonised ER membrane reorganisation and enhanced BH3 mimetic-
mediated apoptosis, in the next chapter, the therapeutic benefits of DHODH inhibitors 
was explored in head and neck squamous cell carcinoma (HNSCC). The results 
indicate that DHODH is highly expressed in HNSCC cell lines, and genetic as well as 
pharmacological inhibition of DHODH reduce clonogenic survival potential in several 
HNSCC cells. Although targeting DHODH could be a promising strategy in HNSCC, 
inhibitors of DHODH do not synergise with other potential chemotherapeutic agents 
namely, cisplatin, A-1331852, S63845, and CB-839. Further studies are required to 
assess whether DHODH inhibitors will be effective as single agents, or in combination 
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1.1. Structural domains of the endoplasmic reticulum 
The endoplasmic reticulum (ER) is an important cellular organelle that is 
involved in many fundamental cellular processes1. Dysfunction of the ER has been 
associated with different diseases, including cancer2–5 . The ER is widely spread 
throughout the cell and exists as a network with distinct morphological domains, such 
as the elongated ER tubules and flattened ER sheets6,7. ER tubules exhibit a cylindrical 
shape, which is maintained by specialised residential proteins, such as the members of 
reticulon family8,9 . Reticulons have  specialised reticulon homology domains (RHD), 
which forms a hairpin like structure for bending the ER membrane to maintain tubular 
architecture10 . In contrast, ER sheets are flattened structures, which appear as a series 
of stacked flat sheets, and each stack connected by helical ramps10 . This architecture 
helps to provide the wide space required for ribosomal binding, protein folding and 
other ER functions. ER sheets are maintained by several proteins, including CLIMP-
63 (cytoskeleton linking membrane protein 63), kinectin-1 (KNT-1) and p180 10,11. 
Ribosomes localise on the ER sheets and are commonly referred to as the rough ER, 
which play an important role in protein synthesis12,13 . In contrast, smooth ER is devoid 
of ribosomes and plays significant role in lipid synthesis and organelle interaction2,14 . 
The lumen of ER is separated from the cytosol and provides the space required for 
important physiological functions like protein folding and other ER mediated 
functions15 . In addition, recent studies have demonstrated that ER tubules form 
extensive branches resulting in the creation of three-way junctions. The key players 
from these junctions are proteins, such as the atlastins (ATL) and lunapark (LNP) 16,17. 
These junctions maintain the ER shape and membrane dynamics18,19.  
 
1.2. ER membrane contacts   
Owing to their widespread distribution throughout the cell, the ER membranes 
form contacts and/or cross-talks with various other cellular organelles, including the 
mitochondria, lysosomes and peroxisomes6,20,21 . These interactions play critical roles 










Figure 1.1. Schematic diagram of ER structural domains. The ER is widely spread 
throughout the cell with distinct morphological domains composed of flattened sheets 
and elongated tubules. ER tubules often form three-way junctions, as result of fusion 
among tubular membranes. Elongated ER tubules interact with several organelles, 












             
                                   
Figure 1.2. Schematic representation of ER membrane organelle contacts. ER 
tubules interact with other organelles, including mitochondria, lysosomes, 










1.2.1. ER-mitochondrial contact sites  
ER membranes interact with the mitochondria at mitochondrial-ER contact 
sites (MERCs) that are crucial hubs for lipid transfer, mitochondrial fission, calcium 
homeostasis, cellular stress, cell survival and cell death22,23. MERCs play a critical role 
in the transfer of calcium from the ER to mitochondria during cell death 24. ER is the 
major site of calcium storage within the cell. The cytosolic calcium enters ER via 
SERCA ATPases and released from the ER via inositol trisphosphate receptors 
(IP3R)25,26 . It has been reported that IP3Rs allow calcium transfer from ER to the 
mitochondria through outer mitochondrial localised voltage dependent anion channel 
(VDAC)26.The coupling of IP3R and VDAC is stabilised by the ER-localised protein, 
Grp7522,26 . This coupling system (IP3R-Grp75-VDAC) helps in the transfer of 
calcium from ER to outer mitochondrial membrane (OMM), which is then exchanged 
to inner mitochondria membrane (IMM) through mitochondria calcium uniporter 
(MCU)22 . It has been reported that any alteration in ER-mitochondria molecular tether 
complex (IP3R-Grp75-VDAC-MCU) will influence cellular stress and cell survival 
mechanisms 24,26–30.  
ER-mitochondrial interface also plays important roles in lipid transfer and 
mitochondrial membrane biogenesis 21,31. In the context of lipid transfer, the major 
phospholipids of mitochondrial membranes, namely phosphatidylethanolamine (PE) 
and phosphatidylcholine (PC), are both synthesised in the ER and later translocated to 
the mitochondria to regulate mitochondrial membrane biogenesis and maintenance 21. 
Similarly, ceramide is another lipid synthesised in ER and translocated to the 
mitochondria to act as a precursor for membrane sphingolipids in mitochondrial 
membrane biogenesis 24,32,33. 
 
1.2.2. ER-lysosomal contact sites  
Lysosomes is one of the key organelles involved in intracellular digestion, it 
contains several acidic enzymes responsible for the breakdown of macromolecules 
into their individual molecules, thus regulating cellular homeostasis including cell 
death and survival34–37. ER-lysosomal contacts play important role in nutrient sharing, 
in this process ER tubule fuse with lysosomes via a SNARE mechanism achieved by 
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syntaxin-7 (STX-7) and VMP7, the ER also play a critical role in ER-lysosomal 
mediated calcium-induced-calcium-release (CICR) process38.In this process, nicotinic 
acid adenine dinucleotide phosphate (NAADP) plays a key role to release lysosomal 
calcium from two pore channel (TPC) channels located in the lysosomal membrane38. 
Lysosomal released calcium further activates ER membrane calcium channels IP3R 
and RyR38. CICR process will help to amplify calcium levels and controlling adequate 
amount of calcium storage in lysosomes and ER. However, the composition of 
organelle interaction is clearly in metabolite exchange but exciting new functions in 
organelle interaction and communication have been discovered38   
 
 
                                  
 
Figure. 1.3. Schematic representation of ER-mitochondrial contacts tether 
complex. ER-mitochondrial tethers often facilitate calcium transfer between ER-






1.2.3. ER-Peroxisomal contacts sites  
ER membranes interact with peroxisomes for membrane biogenesis39,40 and 
lipid transfer39,41,42. PEX proteins, including PEX 3 and PEX19, are synthesised in the 
ER from they are translocated to peroxisomes for membrane maintenance43. However, 
precise molecular mechanism exist between ER-peroxisomal contact sites are still 
unclear39,41,43,44.   
1.2.4. ER-plasma membrane contact sites   
ER-plasma membrane contacts also play important roles in calcium 
homeostasis and the regulation of store operated calcium entry (SOCE)45,46 . ER is the 
main calcium storage unit within the cell47–50. High levels of ER calcium facilitate 
proper protein folding46 . Depletion of ER calcium levels results in the oligomerisation 
of an ER transmembrane stromal interaction molecule (STIM1), which in turn interacts 
with a plasma membrane-bound calcium release-activated calcium modulator 1 
(ORAI1)45,46 . Coupling of STIM1 and ORAI1 results in SOCE to facilitate the 
refilling of the depleted ER calcium stores51–53. Similarly, ER-plasma membrane 
contacts also play critical roles in lipid translocation49,54. It has been reported that lipid 
shuttling often uses tether complexes, such as vesicle associated membrane protein-
associated protein (VAP) and transmembrane protein 16 (TMEM 16)55. 
 
1.3. ER function  
ER is involved in several cellular functions, including protein folding, protein 
quality control, calcium storage, lipid synthesis, sterol biosynthesis, drug 
detoxification and cell death11,24,32,56–59. In the context of lipid biosynthesis and 
regulation, ER synthesises several structural phospholipids, such as 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), as well as ceramides and 
cholesterol60 . The initial steps of ceramide synthesis take place within the ER, 
following which ceramides are transferred to the Golgi complex to aid in the formation 
of complex sphingosine60 . Sphingosine is one of the major lipids in the lipid bilayer. 
Alterations in ER lipid synthesis leads to several disorders, including obesity and 
cancer33,60 . ER also regulates cholesterol biosynthesis, as the rate-limiting step is 
catalysed by the ER resident protein, HMG-CoA reductase (3-hydroxy-3-
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methylglutaryl-CoA reductase)61. Alterations in HMG-CoA reductase are associated 
with several diseases, including smith-lemi-opitz syndrome, Alzheimers disease and 
cardiovascular diseases61 .  
Detoxification is the physiological process responsible for removal of toxic 
substances from body and is mainly carried out by the liver59 . ER in the liver cells 
(hepatocytes) allows a larger surface area and space for detoxifying enzymes. Various 
detoxifying enzymes identified in the ER, such as cytochrome P450, metabolise toxic 
compounds, such as the anti-epileptic drug, phenobarbital62 . Interestingly, chronic 
phenobarbital toxification often changes the entire ER morphology62. Such ER 
morphological changes referred to as anastomosing ER is an adaptive response to deal 
with high concentrations of phenobarbital 62. 
 
1.4. Mitochondrial fission and fusion  
Mitochondria are dynamic organelles and often undergo fission and fusion to 
control their shape and functions7,27,31,63 . Mitochondrial fission is a highly co-
ordinated process in which mitochondria are  divided into two or more independent 
mitochondria7,24 . During mitochondrial fission, ER tubules wrap around the 
mitochondria and marks the fission constriction site at the outer mitochondrial 
membrane (OMM) 7,31,64. This is followed by the translocation of DRP-1 (dynamin 
related protein-1) from the cytosol to OMM7,27,31 . DRP-1 is a GTPase super family 
protein, which upon mitochondrial translocation binds to its receptors, such as MFF 
(mitochondrial fission factor), MiD49 (mitochondrial dynamics of 49 kDa protein) and 
MiD51 (mitochondrial dynamics of 51 kDa protein)31,65. 
Mitochondria also undergo fusion, wherein two or more mitochondria fuse 
together to generate elongated mitochondria31 . Several outer and inner mitochondrial 
proteins, such as mitofusions (MFN1 and MFN2) and OPA1 (optic atrophy1) aid in 










                               
                
Figure 1.4. Schematic representation of mitochondrial fission and fusion. 
Mitochondria are dynamic organelles. Mitochondrial fusion process is mediated by 
MFN1 and MFN2 in the outer mitochondrial membrane and by OPA-1 in the inner 
mitochondrial membrane, whereas mitochondrial fission is mediated by binding of 









1.5. Calcium signalling 
ER calcium signalling is tightly controlled by several influx and efflux 
mechanisms 53,66,67. The efflux of calcium is regulated by IP3Rs (inositol 1,4,5-
trisphophate receptors)68 and RyRs (ryanodine receptors)69 . Increased ER lumenal 
calcium levels often activates IP3 signalling, which involves the cleavage of PIP2 
(phosphatidylinositol 4,5-bisphosphate) to IP3 and DAG (diacylglycerol) with the help 
of phospholipase C 53. Activated IP3 binds to its receptor to facilitate the release of ER 
calcium into cytosol. In contrast, RyRs act as calcium sensors, and get spontaneously 
activated when ER lumen is overloaded with calcium50,66. The influx of ER calcium is 
regulated by SERCA (sarcoendoplasmic reticulum calcium transport ATPase ), which 
accumulates calcium inside ER lumen and regulates ER homeostasis70–73, ER stress 
and apoptosis50,53 . As detailed above, inhibition of SERCA activity depletes ER 
calcium stores and facilitates store operated calcium entry (SOCE) (Figure 1.5) 74–77 
by the interactions of STIM and ORAI proteins (Figure 1.5)50.  
      
 
Figure.1.5. Schematic representation of store operated calcium entry. Normally 
ER calcium influx occurs through SERCA and stored inside ER lumen for maintaining 
ER functions and homeostasis. Inhibition of SERCA by thapsigargin reduces ER 
lumenal calcium levels, which are sensed by ER membrane proteins, such as STIM1/2. 
This helps to refill ER calcium by association with plasma membrane calcium channel 
proteins, such as ORAI1.  
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1.6. ER stress and the unfolded protein response 
The ER plays an important role in protein folding78–81. Newly synthesized 
polypeptides are translocated to the ER lumen via a large transmembrane channel 
called the ER translocon, which is composed of Sec61β protein complex80 . Upon 
translocation, the polypeptides are carefully folded within ER lumen with the help of 
ER chaperones, such as binding immunoglobulin (BIP) and protein disulphide 
isomerase (PDI)79,82 . Correctly folded proteins are then released from ER to the Golgi 
complex for further processing and maturation, and eventually translocated to their 
final destinations4,83 . Proper protein folding is critical for maintaining cellular 
homeostasis, including cell survival and cell death4,84.  
Accumulation of misfolded proteins inside the ER lumen activates the 
unfolded protein response (UPR)4 . The main goal of the UPR is to restore the protein 
folding capacity of the ER as quickly as possible by halting other cellular functions 
that are required for protein synthesis 84.  The UPR signalling pathway is controlled 
through three different stress-sensor proteins, namely PERK (protein kinase RNA-like 
ER kinase), IRE1 (inositol-requiring enzyme 1) and ATF6 (activating transcription 
factor 6)80,84 . In normal conditions, PERK, IRE1 and ATF6 are found bound to BIP 
82,85. Upon UPR stimulation, these interactions are disrupted and BIP is released, which 
leads to the activation of PERK, IRE1 and ATF6 4,80.  Activation of PERK involves 
its dimerization and phosphorylation, followed by the phosphorylation of a eukaryotic 
translation initiation factor 2 alpha (eif2α), which inhibits protein translation and 
enables the cells to restore ER homeostasis4,86 . The active form of IRE1 induces the 
mRNA splicing of x-box binding protein 1(XBP1). Thereafter, the spliced XBP1 
(sXBP1) is translocated to the nucleus, where it binds to an ER stress response element 
promoter and transcribes  several UPR response genes4 .  Dissociation of BIP from 
ATF6 transports the full length ATF6 (p90) to the Golgi complex, where it is 
proteolytically cleaved to ATF6 (p50)80,82 .  The cleaved form of ATF6 (p50) also acts 
as a transcription factor and regulates transcription of UPR response genes4,87 .  While 
activated PERK, IRE1 and ATF6 signal to alleviate ER stress and restore ER 
homeostasis, this is not possible under prolonged ER stress. As a result, the UPR 
mechanisms lead to apoptosis4,88 . It has been reported that CCAAT/ enhancer-binding 
protein homologous protein (CHOP) plays a crucial role in ER stress-mediated 







Figure.1.6. Schematic representation of ER stress and UPR signalling.  Disrupted 
protein folding inside ER lumen often causes ER stress and activates an adaptive 
response called unfolded protein response (UPR). This response is mediated by the 
dissociation of BIP from three ER stress sensors. PERK, IRE1 and ATF6. Following 
dissociation of BIP from PERK becomes activated by dimerization process and its 
downstream activated signal helps to relieve ER stress. Activated IRE1 induces 
splicing of XBP1 mRNA into sXBP1 and its downstream signal process helps to 
relieve ER stress. ATF6 is translocated to the Golgi complex, where it is cleaved into 
an active transcription factor to relieve ER stress. Prolonged ER stress often triggers 




1.7. ER membrane reorganisation  
Although the canonical ER stress response and the UPR have been extensively 
characterised, recent findings have demonstrated a novel form of ER stress, in which 
the ER membranes are reorganised by distinct pharmacological agents, such as 
apogossypol, ivermectin and NDGA (Figure 1.7)90,91.  Such ER membrane 
reorganisation (ERMR) is evolutionary conserved from yeast to humans, as ERMR 
has been observed in fission yeast (Schizosaccharomyces pombe), Chinese hamster 
ovary cells (CHO), mouse embryonic fibroblasts (MEF) as well as in several human 
cell lines91 . The induction of ERMR is rapid and occurs within 30 minutes of exposure 
to the reorganisation inducers91 .  Moreover, ERMR can be completely reversed when 
the drugs are washed out 91.   
ERMR alters vesicular trafficking from ER/Golgi and also attenuates global 
protein synthesis91. Despite such effects, ERMR has been shown to be distinct from 
the UPR, as ERMR occurs even in the absence of new transcription and translation 
and also in cells lacking UPR regulators, such as PERK, IRE1, ATF6, XBP1 and 
CHOP91. It has been reported that reorganisation inducers target calcium homeostasis 
and may promote SOCE91.  Overexpression of STIM1 can induce ERMR and 
inhibitors of SOCE, such as 2-APB (2-aminoethoxydiphenyl borate), can efficiently 
prevent apogossypol-mediated ERMR90 . These findings suggested that there could be 
specific regulatory mechanisms between STIM and SOCE that could modulate 
ERMR. However, silencing the expression levels of SOCE regulators (STIM1 and 
ORAI1) does not alter apogossypol-mediated ERMR.  In addition, extracellular 
supplementation of calcium also does not alter ERMR90, further suggesting that 2-APB 
















Figure. 1.7. Schematic representation of ERMR. ERMR is triggered by several 
chemical compounds, including apogossypol, NDGA, ivermectin, suloctidil and 









1.8. Apoptosis  
Apoptosis is highly conserved pathway and is critical for the development of 
tissues and organisms92–94. It is characterised by the condensation of nucleus, a 
decrease in cell size and plasma membrane blebbing95. An imbalance in apoptosis is a 
common feature of many diseases, including cancer93,96,97. Apoptosis pathway can be 
initiated by either the mitochondrial dependent (intrinsic) (Figure 1.10) or 
mitochondrial independent pathway (extrinsic) (Figure 1.10)92,98–100. The extrinsic 
pathway occurs at the level of cell surface and initiated by the binding of death ligands 
to its receptors. Death ligands like FasL binds to Fas receptor, recruit adaptor proteins 
like Fas associated death domain protein (FADD), to form the death inducing 
signalling complex (DISC), which eventually leads to the activation of caspases -8, -3 
and -792,101 (Figure 1.10). In certain cells the activation of effector caspases by caspase-
8 requires the cleavage of Bid, a member of the BCL-2 family proteins102 (Figure 
1.10). In contrast, the mitochondria play an important role in intrinsic pathway. This 
pathway initiated by the pore formation at outer mitochondrial membrane by a process 
known as mitochondrial outer membrane permeabilization (MOMP)98.  This results in 
the release of cytochrome c from inner mitochondrial membrane to the cytosol99 
(Figure 1.10) . Released cytochrome c binds to an apoptotic protease activation factor-
1 (APAF-1), which in turn recruits procaspase 9 to form the apoptosome98,100. This 
further cleaves procaspase 9 into active caspase 9 and initiates the caspase cascade. 
This pathway is regulated by different members of the BCL-2 family proteins103 
(Figure 1.10).   
The BCL-2 family members share one or more common BCL-2 homology 
(BH) domains such as BH1, BH2, BH3 and BH4, and can be divided into anti-
apoptotic proteins (BCL-2, BCL-XL, BCL-w and MCL-1) and pro-apoptotic proteins 
(Figure 1.8)92,96–98. Proteins that possess only the BH3 domains are referred to as the 
pro-apoptotic BH3 only proteins (Figure 1.8), which can further sub-divided as 
activators (BIM, BID, PUMA) and sensitisers (BAD, NOXA, BIK, BMF). In addition, 
the pro-apoptotic BCL-2 family members include effector proteins, BAX, BAK 
(Figure 1.9).  The activators of BCL-2 family, BIM, BID and PUMA are block the 
anti-apoptotic proteins and can interact with BAX and BAK then induce apoptosis 
(Figure 1.9). The effector proteins of BCL-2 family, BAX, and BAK are inhibited the 
anti-apoptotic proteins BCL-2, BCLXL, MCL-1 (Figure 1.9). Upon induction of 
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apoptosis, the sensitisers BAD and NOXA are inhibit the anti-apoptotic proteins 
(Figure 1.9). For example, BCL-2, BCL-w, and BCL-XL can bind to and inhibit BAD, 
while MCL-1 cannot. Instead, MCL-1 can uniquely bind to NOXA (Figure 1.9). Pro-
apoptotic protein that normally resides in the cytoplasm and upon apoptotic stimuli, 
undergoes conformational changes to translocate to OMM96,98. On the other hand, 
BAK is normally localised on OMM in healthy cells, upon apoptotic stimuli BAK 
undergoes conformational changes and eventually form pore on outer mitochondrial 
membrane92,98. Upon disruption of outer mitochondrial membrane, cytochrome c 
released into cytosol which finally triggers the apoptosis by promoting caspase 
activation (Figure 1.10).   
Cytochrome c is an important component of the mitochondrial electron 
transport chain104–106. The electron transport chain consists of several complexes such 
as, complex I. Complex II, complex III, cytochrome c and complex IV. It has been 
reported that electron transport chain components critically affect cell death and 
survival process105. For example, the loss of electron transport chain components, such 
as cytochrome c affects mitochondrial function and could result in cell death107.  Under 
normal conditions, cytochrome c resides inside mitochondrial cristae and this is 
regulated by optic atrophy 1 (OPA-1)108,109. During apoptosis, OPA-1 is proteolysed, 
which eventually facilitates the release of cytochrome c from the inner mitochondrial 
membrane to the cytosol via BAX and BAK pores110. Released cytochrome c then 
binds to an apoptotic protease activation factor-1 (APAF-1), which eventually recruits 
procaspase 9 to form the apoptosome111.  
Targeting BCL-2 family of proteins is made possible using BH3 mimetics, 
which are small molecule inhibitors that mimic the BH3 domains of BH3-only proteins 
(Figure 1.8)102,112–116. BH3 mimetics bind to the hydrophobic groove of the anti-
apoptotic members to prevent their function and trigger apoptosis102,113 . Specific BH3 
mimetics have now been developed to selectively inhibit BCL-2 (ABT-199)114, BCL-
XL (A-1331852)
117,118 and MCL-1 (A-1210477)118. ABT 199 (venetoclax), a specific 
BCL-2 inhibitor, was developed for the treatment of CLL and is the first FDA-




Figure. 1.8. The schematic representation of the structural features of anti-
apoptotic and pro-apoptotic BCL-2 proteins. The BCL-2 family proteins have 




Figure. 1.9. The schematic representation of the major members of BCL-2 family 
of proteins and their interactions. The anti-apoptotic BCL-2 family of proteins 
(BCL-2, BCL-w, BCL-XL and MCL-1 are suggested to interacted with both 
sensitisers, activators and effector members to facilitate the regulation of apoptosis 
within a cell. The activators (BH3-only proteins) exhibit more specific interaction 
patterns for each anti-apoptotic member. For example, the anti-apoptotic members 
such as BCL-2, BCL-w and BCL-XL can interact with and inhibit BAD. While MCL-








Figure 1.10. The schematic representation of apoptosis. Cells undergo apoptosis 
either via the extrinsic or intrinsic pathway. Extrinsic apoptosis pathway is initiated by 
the death receptors and ligands in the plasm membrane. Binding of death ligand to 
death receptor facilitates DISC assembly, which eventually activates procaspase-8 and 
BID. Upon activation, truncated BID is eventually translocated to the mitochondria 
and facilitates BAX/BAK-mediated release of cytochrome c. Intrinsic apoptosis 
occurs at the level of mitochondria, resulting in BAX/BAK activation and 
oligomerisation at the OMM to facilitate cytochrome c release from mitochondria to 










1.9. Pyrimidine metabolism  
Pyrimidine synthesis is an essential metabolic pathway in the cells. 
Intermediates of this pathway include CTP, TTP and UTP, all of which act as essential 
building blocks for DNA and RNA123–128. Pyrimidines also act as precursors for UDP-
sugars (glycogen synthesis), energy source (CTP) and cofactors (NAD, FAD)123,127.  
Pyrimidine biosynthesis also plays critical roles in various diseases, including 
cancer127–131. Cancer cells use high levels of pyrimidines127,128 and any alteration in 
pyrimidine synthesis lowers the pyrimidine pool and suppresses growth of the cancer 
cell132. 
Pyrimidine biosynthesis is regulated either by salvage or de novo 
pathways123,127. In salvage pathway, pyrimidine nucleotides are obtained from 
recycled bases that are released during degradation of RNA and DNA123,127. De novo 
pyrimidine biosynthesis is a coordinated process which begins with glutamine and 
carbon dioxide, which synthesise carbamoyl phosphate by carbamoyl phosphate 
synthase (Figure 1.11)123,127. Carbamoyl phosphate then combines with aspartate to 
form carbamoyl aspartate, a reaction catalysed by aspartate transcarbamoylase123,127. 
Carbamoyl aspartate, thus formed, is then converted to dihydroorotate by 
dihydroorotase (Figure 1.11)123,127. Dihydroorotate is then converted to orotate by the 
enzyme dihydroorotate dehydrogenase (DHODH)126. DHODH enzyme present inside 
mitochondria and its activity has been used a target in treating several diseases 
included cancer, rheumatoid arthritis, malaria, and multiple sclerosis128,131,132. Finally, 
orotate is synthesised by orotate phosphoribosyl transferase, which eventually forms 
UMP, UDP and UTP by phosphate exchange mechanism (Figure 1.11)123 .  
DHODH consists of N-terminal and C-terminal domains interconnected with 
a loop to form an active catalytic region (Figure 1.12)130,133 . This catalytic region is 














Figure 1.11. De novo biosynthesis of pyrimidine nucleotide. The pathway consists 
of the six enzymatic reaction catalysed by carbamoyl phosphate synthase, aspartate 




















                              
 
Figure. 1.12. DHODH structure. The N-terminal helical domain is coloured light 
blue. The N and C terminal connected loop is coloured dark blue, helices are coloured 













1.10. DHODH inhibitors 
 
DHODH inhibitors were designed to inhibit pyrimidine biosynthesis and 
deplete pyrimidines to inhibit DNA and RNA synthesis129,135–138 . There are several 
inhibitors developed against DHODH enzyme, including brequinar137, leflunomide136, 
teriflunomide139,140, Bayer (BAY2402234)129 and ASLAN003 (Figure 1.13)138. 
DHODH inhibitors have proven to be efficient in the treatment of several diseases, 
including rheumatoid arthritis and haematological cancers127127,128. Brequinar has been 
used to treat rheumatoid arthritis, head and neck cancer and other cancers137. Reports 
suggested that Brequinar has not shown significant effect on early phase clinical trials 
of head and neck , breast and ovarian cancer137,141,142. In addition, the toxicity and 
narrow therapeutic window of this compound has limited its clinical use127. 
Leflunomide (Arava) was later designed against DHODH for treating rheumatoid 
arthritis and this drug successfully gained FDA approval in 1999143–145 . Several 
findings report that leflunomide has a short half-life and its treatment often causes 
severe liver toxicity within 6 months145 . Due to liver toxicity and weak potency, this 
compound was later withdrawn from FDA approval list and discontinued. Later, 
leflunomide was structurally modified into another compound and named as 
teriflunomide145,146 . Teriflunomide is the active derivative of leflunomide and the only 
difference between these two drugs is the opening of the isoxazole ring. Upon oral 
administration, the isoxazole ring of leflunomide opens and teriflunomide is formed 
(Figure 1.14).139 Teriflunomide was successfully investigated in clinical trials and 
received FDA approval in 2012.  
Although numerous inhibitors are currently available to selectively target 
DHODH (Figure 1.13), it is unclear as to how these inhibitors inhibit tumor growth. 
Recent studies using the CRISPR/Cas9 gene knockout strategy reveals that genetic 
knockout of DHODH effectively inhibited tumor growth130,147. This could well be due 
to their roles in pyrimidine biosynthesis, but more studies need to be performed to 








Figure. 1.13. The chemical structure of DHODH inhibitors.  
 
 
         







1.11. Objectives of this study  
A current challenge in cancer therapy is drug resistance. Growing reports suggest 
that cancer cells acquire resistance to chemotherapeutic drugs through different 
mechanisms, which include a failure to undergo apoptosis. Since ER-mitochondria 
communication has been reported to have a significant impact on apoptosis, this study 
is aimed at gaining a better understanding of the functional consequences of ER-
mitochondria communication in the context of cancer cell death. In this study, 
reorganisation of ER membranes (ERMR) is used as a tool to study ER-mitochondria 
communication further. In addition, this study is further extended to examine the 
therapeutic benefits of de novo pyrimidine synthesis inhibitors in head and neck 
squamosal cell carcinoma.  
 
The following question have been addressed in this thesis:  
 
1. To examine whether ERMR-induced reorganisation is restricted to ER 
membranes or other organelles. 
 
2. To investigate impact of ERMR on mitochondrial-mediated apoptosis. 
 
 
3. To investigate whether ERMR inhibitors modulate ERMR regulated apoptosis.  
 
4. To explore the potential of de novo pyrimidine biosynthesis inhibitors in 
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2.1. Cell culture  
All cell culture work was carried out using standard aseptic techniques and 
maintained according to the guidelines provided by the vendors. Briefly, cell lines 
were grown in culture flasks with recommended growth media containing 10 % foetal 
bovine serum (Life Technologies, catalogue number: 10270106). The cells were 
monitored daily and cells were passaged when they reached at 60-70 % confluency. 
Upon reaching confluence, the suspension cells were dispersed and split further using 
fresh media. For adherent cells, the media was aspirated from the flask and cells 
washed with phosphate buffered saline (PBS; Fisher Scientific, catalogue number: 
11510546) before adding the trypsin-EDTA solution (Life Technologies, catalogue 
number: 15400054) and incubated for 2 min at 37°C to allow cells to detach from flask. 
Upon detachment, fresh media was added to cells to stop trypsinisation and cells were 
passaged further. All cultured cells were maintained in an incubator at 37°C with 5% 
carbon dioxide (CO2). 
 
2.2. Cell lines  
All cell lines used in this study are categorised into individual culture media, cell 
line origin and supplier information as summarised in the table 2.1 below. RPMI 
indicates Roswell Park Memorial Institute 1640, purchased form Life Technologies, 
catalogue number: 61870044. DMEM indicates Dulbecco’s Modified Eagle Medium 
purchased from Life Technologies, catalogue number: 32430100. MEM indicates 
Minimum Essential Medium Eagle, purchased from Sigma, catalogue number: 





Tumour origin Source 
H1299 RPMI 






Mantle cell lymphoma 
(MCL) 













Chronic myeloid leukaemia 
(CML) 







Multiple myeloma ATCC 
HeLa DMEM Cervical carcinoma ATCC 





UM-SCC - 1 
DMEM + 
NEAA 
Head and neck squamous 
cell carcinoma (HNSCC); 




UM-SCC - 11B 
DMEM + 
NEAA 
HNSCC isolated form 
larynx 
UM-SCC - 81B 
DMEM + 
NEAA 










Table 2.1 Table showing all the cell lines used throughout this study. 
 
2.3. Cell line authentication  
Total genomic DNA was isolated using DNA isolation kit (Qiagen, Cambridge, 
UK) according to manufacturer’s recommendation. Isolated samples were then sent to 
the University of Liverpool cell line authenticity facility. Briefly, samples were 
subjected to short tandem repeat (STR) profiling using GenePrint 10 (Promega, 














UMSCC - 1 100% 
UMSCC - 11B 100% 
UMSCC - 81B 100% 
FaDu Newly purchased/ Not-tested 
 
Table 2.2. Table showing cell lines were authenticated using STR profiling and 
matched against multiple databases. 
 
2.4. Reagents and compounds  
Reagents, chemicals and buffers were obtained from Sigma-Aldrich/ Merck 
(Darmstadt, Germany) unless otherwise specified, such as Selleck (Houston, TX, 
USA), Abbvie (Chicago, IL, USA), Sigma (Darmstadt, Germany) and Apex 
Biotechnology (Houston, TX, USA). Reagents and compounds and supplier 
information are summarised in the table 2.3 below.  
 
Inhibitors Target/ Function Source 
ABT- 199 BCL-2 Selleck 
A-1331852 BCL-XL Abbvie 
A-1210477 MCL-1 Abbvie 
S63845 MCL-1 Selleck 
Z-VAD.fmk Caspases Selleck 
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CCCP Mitochondrial uncoupler Sigma 
Apogossypol 
ER membrane reorganisation 




ERMR inducer and antioxidant Sigma 
Ivermectin ERMR inducer and anthelmintic Sigma 
Terfenadine ERMR inducer and antihistamine Sigma 
Suloctidil ERMR inducer and vasodilator Sigma 
Teriflunomide DHODH  Sigma 
Leflunomide DHODH  Sigma 
Orotate Intermediate of pyrimidine pathway Sigma 
Uridine Intermediate of pyrimidine pathway Sigma 
Cisplatin Covalent DNA adducts* Selleck 
CB 839 Glutaminase 1 (GLS 1) Selleck 
 
Table 2.3. Inhibitors used this study.  
*Cisplatin is a covalent DNA adduct, which induces DNA damage by covalently 
binding to the DNA at N7 position of purine. 
 
2.5. Antibodies  
Antibodies were purchased from Abcam (Cambridge, UK), Sigma (Darmstadt, 
Germany), BD BioSciences (CA, USA),  CST (Cell Signalling Technology, MA, 
USA), Enzo Biochem Inc (NY, USA), Calbiochem Research Biochemicals (now 
Merck), Santa Cruz Biotechonology (CA, USA) or DSHB (Developmental Studies 
Hybridoma Bank, The university of Iowa, Iowa). ICC indicates 
immunocytochemistry. WB indicates western blot. FACS indicates fluorescence-





Antibody Source Catalogue number Isotype Application 
Endoplasmic reticulum 
BAP31 Abcam Ab37120 Rabbit IgG ICC 
RTN4 Abcam Ab47085 Rabbit IgG ICC 
CLIMP 63 Enzo ALX-804-604 Mouse IgG2a ICC 
KNT-1 Sigma HPA003178 Rabbit IgG ICC 
Bip Abcam 21685 Rabbit IgG ICC, WB 
PDI Abcam Ab2792 Mouse IgG2a ICC, WB 
CHOP Abcam Ab11419 Mouse IgG WB 
Golgi complex and lysosomes 
GM130 BD 610822 Rabbit IgG ICC 
LAMP 1 DSHB AB 528127 Mouse IgG1 ICC 
Mitochondria 
HSP60 BD 611562 Mouse IgG1 ICC 
DRP-1 BD 611113 Mouse IgG1 WB 
DRP-1 CST 8570 Rabbit IgG ICC 
MFN-1 CST 13196 Rabbit IgG WB 
MFN-2 CST 9482 Rabbit IgG WB 
Opa1 BD 612607 Mouse IgG1 WB 
Apoptosis 
BAX (6A7) Enzo ALX-804-224-C100 Mouse IgG1 FACS 
BAK (AB-1) Calbio AM-03 Mouse IgG2a ICC, FACS 
Cytochrome c CST 4272 Rabbit IgG ICC, WB 
Caspase 3 CST 9662 Rabbit IgG WB 
Caspase 7 CST 9494 Mouse IgG1 WB 
cl. caspase 9 CST 9505 Rabbit IgG WB 
cl. PARP CST 5625 Rabbit IgG WB 
Miscellaneous 
GAPDH SC Sc-25778 Rabbit IgG WB 
Actin SC Sc-1616R Rabbit IgG WB 
DHODH Sigma HPA011942 Rabbit IgG WB 
Table 2.4. List of antibodies used in this study.  
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2.6. RNA interference  
Small interfering RNAs (siRNAs) were obtained from Qiagen (Cambridge, 
UK). Transfection were carried out according to the manufacturer’s instructions. 
siRNAs were transfected into cells using a final concentration of 10 nM, using 
optiMEM reduced serum media (Life Technologies) and interferin transfection reagent 
(Polyplus, Illkirch, France). RNA interference and sequence targeted information are 




















Table 2.5. List of siRNAs used in this study. 
 
2.7. Transient transfection  
Plasmid transfection was performed as per manufacturer’s instructions. Briefly, 
cells were seeded one day before transfection at determined density to reach 80% 
confluence. Cells were then transfected with Sec61β-GFP plasmid (from Prof. T. 
Rapoport, Harvard, Boston, USA; Addgene plasmid 15108) using TransIT-LT-1 
transfection reagent (Mirus Bio LLC, Madison, WI, USA). The ratio DNA (g): 
transfection reagent (l) was 1:3. Transfection efficiency was observed in an EVOS 





2.8. Western blotting  
Western blotting was carried out according to a standard protocol. Briefly, gels 
were made in-house with Protogel acrylamide (30%) (National Diognostics, Atlanta 
GA, USA), lower gel buffer (1.5 M Tris-HCL, 0.4% SDS, pH 8.8), upper gel buffer 
(Tris-HCL 0.5 M, 0.4% SDS, pH 6.8), 10% ammonium persulphate (APS)  and 
tetramethylethyllenediamine (TEMED). Cells were collected and pellets were lysed 
with radioimmunoprecipitation assay (RIPA) lysis buffer (10 mM Tris- (pH 8.0), 1mM 
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1 % sodium deoxycholate, 0.1% sodium 
dodecylsulfate (SDS), 140 mM NaCl, 20 M MG-132 and one protease inhibitor tablet 
(Roche, Basel, Switzerland). After lysis, total protein content was determined using 
calorimetric protein assay (Bio-Rad protein assay Dye reagent, BioRad, CA, USA) 
and readings were measured with a spectrophotometer (Eppendorf, Hamburg, 
Germany). After protein concentration determination, samples were prepared using 
4X NuPAGE LDS sample buffer (Life Technologies) and boiled for 5 min at 70°C. 
Cell lysates were fractionated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide 
gel electrophoresis) in electrode buffer (25mM Tris-HCL, 192 mM glycine, 10% SDS) 
at 130 V for 120 min and then transferred to a nitrocellulose membrane (VWR, 
Radnor, PA, USA) in transfer buffer (25 mM Tris-HCL, 192 mM glycine, 20% 
methanol) at 100 V for 100 min. After transfer, membranes were blocked with 5% 
(W/V) non-fat milk with TBS-T (Tris-buffered saline with 0.1% Tween, 20 mM Tris-
HCL, 150 mM NaCl, 0.1% Tween-20) for 30 min. The blocked membrane was washed 
once with TBS-T and incubated with primary antibodies at 4° C overnight. Membranes 
were washed with TBS-T 3 times for 5 min and incubated with anti-mouse or anti-
rabbit IgG HRP-linked secondary antibodies (Cell Signalling Technology) for 1 h, and 
developed with ECL system (GE Healthcare, IL, USA) using a ChemiDoc imaging 
system (BioRad, CA, USA). 
 
2.9. Cytochrome c release  
Harvested cells were washed with ice-cold PBS and resuspended in 
mitochondrial isolation buffer (250 mM sucrose, 20 mM HEPES, pH 7.4, 5 mM MgCl2 
and 10 mM KCL) containing 0.05 % digitonin. Cells were left on ice for 10 min 
followed by centrifugation at 13000 g for 3 min. The supernatant contained the light 
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membrane and cytosolic fraction whereas the pellet contained the heavy membrane 
fraction that is enriched with mitochondria. Both isolated fractions were analysed by 
western blotting.  
 
2.10. Clonogenic survival  
Cells were seeded at a recommended density in a 12 well plate. On the first day after 
seeding, the growth medium was replaced with new growth medium and then cells 
were exposed to drugs as per experimental design. Subsequently, cells were daily 
monitored for colony formation.  Once the colonies are grown (corresponding to nearly 
50-60 cells per colony), they were washed with PBS then fixed with fixing solution 
(1:7 v/v ratio acetic acid to methanol) for 5 min at room temperature. Following 
fixation, colonies were stained with staining solution (20 ml methanol, 80 ml H2O, 0.5 
g crystal violet) for 1 h at room temperature. Then, colonies were washed with tap 
water and left for drying. Colonies were later counted using a Gel Count instrument 
(Oxford Optronix, Oxford, UK), and survival fraction was calculated using the 
following formula: 
Platting efficiency (PE)* = Colony counted/ cells pated 
% Survival Fraction = Colony counted/ (Cells plated x Plating efficiency) x100 
*Plating efficiency is one of the parameters normally used to determine number of 
colonies originate from single cells.  
2.11. Flow cytometry  
To measure the extent of apoptosis by assessing phosphatidylserine (PS) 
externalisation, adherent cells were collected and trypsinised before being pelleted, 
whereas the suspension cells were collected directly into tubes. Cell pellets were 
resuspended in 500 µl of 1X annexin binding buffer (10 mM HEPES, 140 mM NaCl, 
2.5 mM CaCl2, pH 7.4) with annexin-V-FITC (made in-house; 1:20,000 dilution; 
dilution was optimised to generate similar results against commercially purchased 
annexin V) and incubated at room temperature for minimum 8 min. 5 µl of 1 mg/ml 
propidium iodide (PI) (Sigma-Aldrich/Merk, Darmatadt, Germany) was added to cell 
suspension just before analysis. For BAX and BAK activation, cells were collected 
and fixed with 1% paraformaldehyde (PFA) at room temperature for 10 min. The cells 
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were then re-suspended in FACS buffer (0.1% saponin, 0.5% bovine serum albumin 
(BSA) in PBS) for 10 min. The fixed cells were then incubated with the primary 
antibody (anti-BAK AB-1 or anti-BAX 6A7; 0.1 mg/ml) diluted in FACS buffer for 1 
h at 4°C. Cells were then pelleted by centrifugation before incubation with species-
specific secondary antibody (goat-anti-mouse IgG-AlexaFluor-488 conjugated 
secondary antibody), diluted in FACS buffer for 1 h at 4°C. The extent of apoptosis, 
BAK/ BAX activation was detected by Attune NxT flow cytometer (ThermoFisher). 
10,000 events per sample were recorded and a minimum of 3 replicates were assessed 
for each experiment.   
 
2.12. Immunocytochemistry  
One day prior to experiment, cells were seeded on sterile coverslips in a 24 
well plate to reach 60-70% confluence at the time of experimental treatment. Cells 
were fixed with 4% (w/v) PFA for 10 min at room temperature. Cells were 
permeabilised with 0.5% (v/v) Triton X-100 in PBS for 10 min at room temperature. 
After permeabilization, cells were incubated with primary antibody, diluted in 3% 
BSA in PBS for 1 h. After washing, cells were then incubated with species-specific 
secondary antibody (AlexaFluor, Life Technologies) diluted in 3% BSA in PBS for 1 
h, followed by nuclear staining with Hoechst 33342 in 3% BSA in PBS. The coverslips 
were then mounted in glass slides with Polymount (Polysciences, PA, USA). Finally, 
cells were imaged in 3i Marianas spinning disk confocal microscope fitted with a plan-
Apochromat 63x/1.4NA Oil objective, M27 and a Hamamatsu ORCA-Flash4.0 v2 
sCMOS Camera (all from Intelligent Imaging Innovation, GmbH, Germany). 
 
2.13. Visualisation and Quantification of ER membrane reorganisation   
Cells exposed to ER membrane reorganisation inducers for indicated times 
were first immunostained with ER membrane antibodies (RTN4 or BAP31). After, 
immunostaining, cells were imaged with 3i Marians spinning disk confocal 
microscope to assess ER membrane reorganization. Normal ER looks widely spread 
within the cell whereas reorganised ER appears like membranous bundles of 
aggregates within the cells. Upon exposure to apogossypol, a cell may contain 
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anywhere from 20-100 ER membrane aggregates, when visualised under confocal 
microscopy. Since the number of ER membrane aggregates was highly inconsistent 
among the different cells, cells that exhibited ER membrane aggregates regardless of 
the number of aggregates, were quantified as cells exhibiting ERMR. Cells that 
contained no detectable ERMR was identified as normal ER. Thus, the quantification 
of ERMR was performed by counting the extent of ERMR (number of cells exhibiting 
ERMR) from several pictures acquired in a confocal microscope of at least 100 cells 
from 3 independent experiments.  
 
2.14. Statistics  
For time-course studies, a two-way ANOVA was performed. All other studies 
were analysed for statistical significance with one-way ANOVA and the asterisks 
depicted correspond to the following p values:  * for p ≤ 0.05, ** for p ≤ 0.005 and 
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3.1. Background  
ER-mitochondria contacts control multiple cellular processes, including 
calcium signalling , lipid synthesis, mitochondrial fission and cell death27,31,33,60,148,149. 
Recent studies have suggested that ER membranes play a significant role in regulating 
mitochondria structural dynamics and functions22,30,51. ER membranes achieve this by 
physically wrapping around the mitochondria, thus aiding in mitochondrial division 
and other mitochondrial functions7,31. The link between the ER-mitochondrial contacts 
and apoptosis remains poorly understood. An understanding of how ER-mitochondria 
contacts regulate mitochondrial apoptosis is critical to improve therapy in several 
cancers, as most chemotherapeutic agents kill cancer cells by inducing the intrinsic 
apoptotic pathway. Previous studies have demonstrated a novel cellular stress response 
characterised by reversible reorganisation of ER membrane reorganisation (ERMR), 
following exposure of cells to wide variety of drugs, such as apogossypol, ivermectin, 
terfenadine, suloctidil and other agents90,91 (Figure 3.1).  
Normally, ER is widely spread throughout the cell whereas reorganised ER 
membranes appear as clusters of ER membrane aggregates within the cell91.  From 
electron microscopy, the aggregates appear to be largely devoid of ribosomes, and 
could therefore be part of smooth ER (Figure 3.1). It does not appear to have a 
consistent shape as they often manifest as bundles of membranes. Although the 
composition of these membranes is yet to be characterised, the reversible nature of 
these aggregates indirectly reveal that the chemical composition of these lipid 
membranes may not be too different from regular ER membranes. Nevertheless, it is 
striking to note that this phenomena is evolutionary conserved from yeast to humans, 
as ERMR has been observed in fission yeast (schizosaccharomyces pombe), Chinese 
hamster ovary cells (CHO), mouse embryonic fibroblasts (MEF) as well as in several 
human cell lines91 . Furthermore, ERMR modulates ER associated functions, such as 
the vesicular trafficking between ER exit sites and the Golgi complex. A drastic 
attenuation of global protein synthesis has also been associated with ERMR91. 
Although these events result in a stress response, ERMR appears to be distinct from 
classical ER stress pathway and the unfolded protein response (UPR). UPR is well-
studied pathway associated with the transcription, translation and activation of specific 
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genes and transcriptional factors, which are aimed at maintaining ER homeostasis, and 
under prolonged stress, triggering cell death150. ERMR occurs even in the absence of 
transcription and translation and also in cells lacking UPR regulators, such as PERK, 
IRE1, ATF6, XBP1 and CHOP151. It has been reported that ERMR can be induced by  
downregulation of an anterograde transport protein (α SNAP), retrograde transport 
protein (syntaxin 18), anti-apoptotic protein (MCL-1) as well as by an upregulation of 
a SOCE protein (STIM 1)90. This indicates that ERMR could be associated with 
diverse physiological functions, such as vesicular trafficking, calcium signalling as 




Figure 3.1. Apogossypol induces extensive ERMR in several cell lines. HeLa, CLL 
and Jurkat T cells were exposed to apogossypol (20 ) for 16 h and subjected to 
electron microscopy. The yellow arrow heads indicate ER membranes. Scale bar: 10 
m. (Image adapted from Varadarajan et al., 2019)90. 
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The original study describing ERMR observed that mitochondrial structure 
largely remained unchanged in cells exposed to ERMR inducers91 .  However, given 
the recent literature linking ER membranes and mitochondrial dynamics. It was 
speculated that modulation of ER membrane morphology might affect ER-
mitochondria contacts, mitochondrial dynamics and as a result, the intrinsic pathway 
of apoptosis. To study this hypothesis, apogossypol was used as a tool compound to 
induce ERMR and then studied its impact on apoptosis.  
The specific questions that will be addressed in this chapter are as follows: 
(1) Do the reorganised ER membranes localise to specific subsites of the ER (such as 
the lumen, tubules or sheets)? 
(2)  What is the effect of ERMR on other closely related organelles, such as the ER-
Golgi intermediate compartment, Golgi complex, lysosomes and mitochondria? 
(3) Do the reorganised ER membranes regulate mitochondrial membrane fusion-
fission dynamics? 




3.2. ERMR appears to occur at the site of ER tubule  
To confirm whether apogossypol induced ERMR, MDCKII cells were 
transfected with a widely recognised ER membrane marker, sec61β7,152, that is fused 
with a GFP-tag. Sec61β is a translocon that spans across the ER membranes152, and 
facilitates the translocation of nascent polypeptides across ER membranes for further 
protein maturation. MDCKII cells were chosen for this study because the ER 
membranes are extensively spread in these cells with well-defined tubules and sheets, 
as evident in Figure 3.2. Most cell lines (other than MDCKII and COS-7) do not have 
clearly distinguishable ER tubules and sheets, and scientists often rely on super 
resolution microscopy to make this distinction. However, in the Sec61β-transfected 
MDCKII cells, exposure of apogossypol (20 µM) for 4 h (time of exposure optimised 
based on previous findings90) resulted in a dramatic reorganisation of ER membranes, 
at the ER tubules, and the sheets remained largely excluded from the reorganised ER 
membranes (Figure 3.2). 
 
Figure 3.2. Apogossypol induces extensive ERMR in Sec61 overexpressed cells. 
MDCKII cells were transfected with Sec61β-GFP (ER marker) and then cells were 
exposed to apogossypol (20 M) for 4 h. After treatment, the cells were fixed and 
imaged with 3i Marians spinning disk confocal microscope to assess ER membrane 
reorganization. Yellow arrow indicates ER tubule; red arrow indicates ER sheets. All 






3.3. ERMR involves the reorganisation of ER tubules 
Although the previous observations in the MDCKII cells revealed that ERMR 
occurred at the levels of ER tubules and not sheets, further confirmation was required 
to convincingly demonstrate this. RTN4 (reticulon-4) is a protein that is localised to 
the tubular ER and is responsible for regulating ER tubular morphogenesis through 
promoting tubular production and extension14,153–155. BAP31 (B- cell receptor 
associated protein of 31kDa) is another protein that is localised to the tubular ER8,156–
158 . Hence, these tubular markers were used to check whether apogossypol-induced 
ERMR localised within ER tubules. For this experiment, cells were exposed to 
apogossypol (20 M) for 4 h, and then immunostained with ER tubule markers RTN4 
or BAP31. In these cells, exposure to apogossypol resulted in extensive ERMR, to 
which both RTN4 and BAP31 appeared to redistribute (Figure 3.3 a-b). Moreover, 
RTN4 and BAP31 exhibited a perfect colocalisation on the reorganised ER membranes 
(Figure 3.4). Taken together, these results strongly suggested that ER tubules played a 
significant role in ERMR. However, whether other parts of ER, such as the sheets or 
lumen are involved in ERMR remains to be studied. 
 
3.4. ERMR does not involve ER sheets or ER lumen 
ER sheets are relatively flat in structure and appear stacked together7. ER sheets 
have several resident proteins, including CLIMP-63 (cytoskeleton linking membrane 
protein 63), also referred as CKPA-4 (cytoskeleton associated protein 4)159 . CLIMP-
63 is widely distributed throughout the ER sheets and responsible for the generation 
and maintenance of ER sheets. Kinectin-1 (KNT-1)159 and p180159 are other ER sheet-
resident proteins. KNT-1 widely spans throughout the ER sheets and acts as a scaffold 
protein to maintain ER sheets7. To assess whether ERMR is localised to the ER sheets, 
cells were exposed to apogossypol (20 M) for 4 h and co-stained with ER sheets 
markers (CLIMP-63 or KNT-1). As a positive control, cells were also stained with 
previously mentioned ER tubule markers (RTN4 or BAP31). The results showed that 
unlike BAP31or RTN4 that immediately redistributed to the ERMR, neither CLIMP-
63 nor KNT-1 resulted in a similar redistribution (Figure.3.5 a-b). Thus, it was 
concluded that apogossypol-induced ERMR does not occur within ER sheets, and that 









Figure 3.3. ERMR colocalises with ER tubule markers. HeLa cells were exposed 
to apogossypol (20 M) for 4 h. The cells were then immunostained with ER tubule 
markers a) BAP31 and b) RTN4. All experiments were independently performed three 














Figure 3.4. ERMR occurs at the level of ER tubules. HeLa cells were exposed to 
apogossypol (20 M) for 4 h. The cells were then immunostained for ER tubule 
markers BAP31 and RTN4. All experiments were independently performed three 










Next, I examined whether ERMR involved the lumenal portions of the ER. ER 
lumen provides lumenal space for several important cellular processes, including 
protein folding. The ER lumen is enriched with several ER lumenal resident proteins, 
including BIP83,156,160,161 (binding immunoglobulin protein) and PDI161 (protein 
disulphide isomerase). BIP acts as an ER stress sensor43. Upon ER stress, BIP 
dissociates from other ER stress response proteins, such as PERK, IRE1, ATF6 and 
eventually triggering an adaptive signal to recover the cells from ER stress162,163. 
Similarly, PDI functions as a molecular chaperone and aids in protein folding process 
to maintain ER homeostasis163 . Hence, these proteins were used as lumenal markers 
to check whether apogossypol-induced ERMR localised to the ER lumen. For this, 
cells were exposed with apogossypol (20 µM) for 4 h and then co-stained with ER 
lumen markers (BIP or PDI) along with an ER tubule marker (BAP31).  The results 
showed that unlike BAP31 that immediately redistributed to the ERMR, neither BIP 
nor PDI resulted in a similar redistribution (Figure.3.6). Thus, it was concluded that 
apogossypol-induced ERMR does not occur within ER lumen, and that ERMR was 
restricted to ER tubules.  
 
 
3.5. ERMR does not colocalise with ER tubule but alters the distribution of 
ERGIC and Golgi complex  
ERGIC, located between ER and Golgi complex, helps to transport cargo 
proteins from the ER to the Golgi complex for further processing14. ERGIC-53164,165  
is a protein predominantly localised to the ERGIC and responsible for the export of 
glycoproteins from ER to Golgi complex. GM130 is a widely distributed protein in the 
Golgi complex166,167. To check whether apogossypol-induced ERMR formed inside 
ERGIC and Golgi complex, cells were exposed to apogossypol (20 µM) for 4 h and 
labelled with ERGIC-53 or GM130, along with RTN-4, as an ER tubule marker. The 
results showed that unlike BAP31 that immediately redistributed to the ERMR, neither 
ERGIC-53 nor GM130 redistributed to the reorganised ER membranes (Figures 3.7 a 
and b). However, apogossypol-induced ERMR dispersed the Golgi complex (Figure 
3.7 b), as previously observed91. Similarly, a modest dispersal of ERGIC-53 was also 








Figure 3.5. ERMR does not involve ER sheets. HeLa cells were exposed to 
apogossypol (20 M) for 4 h. Cells were then co-stained for an ER sheet marker 
(CLIMP-63 or KNT-1) or an ER tubular marker (BAP31 or RTN4). All experiments 








Figure 3.6. ERMR does not occur within the ER lumen. HeLa cells were exposed 
to apogossypol (20 M) for 4 h. Cells were then co-stained for an ER lumenal marker 
(BIP or PDI) with an ER tubular marker (BAP31). All experiments were independently 




3.6. ERMR does not colocalise with membranes of mitochondria or lysosomes 
ER has been shown to interact with other organelles, including lysosomes and 
mitochondria168,169. Lysosomal-associated membrane proteins (LAMP) including 
LAMP 1 and 2 are predominately distributed in the lysosomes and responsible for 
maintaining lysosomal structure169. Similarly, a mitochondrial chaperone, HSP60 
(heat shock protein 60) was used as a mitochondrial marker170. Cells, transiently 
transfected with an ER marker (Sec61β-GFP), were exposed to apogossypol (20 µM) 
for 4 h and then immunostained with the chosen lysosomal and mitochondrial markers. 
The results showed that apogossypol-induced ERMR does not result in the 
redistribution of LAMP 1 or HSP60 (Figure 3.8), thus confirming that ERMR is only 
restricted to ER tubules and not to other cellular organelles, such as the lysosomes and 
mitochondria.  
 
3.7. ERMR antagonises CCCP and A-1210477-mediated mitochondrial 
fission  
Previous results strongly suggested that ERMR is restricted to ER tubules 
(Figure 3.2-3.8). It has been reported that ER tubules play an important role in 
mitochondrial dynamics7,171, during which ER tubules wrap around mitochondria to 
facilitate mitochondrial fission31,168. Since, mitochondrial proton uncoupler (CCCP; 
carbonyl cyanide m-chlorophenyl hydrazine)172,173 and A-1210477 (MCL-1 inhibitor) 
induce extensive mitochondrial fission174,175, cells were pre-exposed to apogossypol 
(20 µM) for 1 h (apogossypol still present throughout the experiment) and then 
exposed to CCCP or A-1210477. The cells were then co-stained with HSP60 
(mitochondria marker) and RTN4 (ER marker). The results showed both CCCP and 
A-1210477 mediated mitochondrial fission as evidenced by the HSP-60 staining 
(Figure.3.9 a-c) , consistent with previous findings reporting mitochondrial fission174. 
Apogossypol-induced ERMR did not result in mitochondrial fission on its own but 
was efficient in preventing both CCCP and A-1210477-mediated mitochondrial fission 
(Figure.3.9 b-c). The extent of mitochondrial fission (appeared as fragmented 
mitochondria) was quantified by counting around 100 cells from 3 independent 










Figure 3.7. ERMR does not occur within the ER-Golgi intermediate 
compartment and Golgi complex.  a) HeLa cells were transfected with ERGIC-53-
GFP. Following transfection, the cells were exposed to apogossypol (20 M) for 4 h. 
After treatment, cells were immunostained with the ER tubular marker BAP31. b) 
HeLa cells treated as before were co-stained for GM130 and RTN4. All experiments 










Figure 3.8. ERMR does not appear to involve lysosomes or mitochondria. HeLa 
cells were transfected with an ER marker (Sec61β-GFP). Following transfection, the 
cells were exposed to apogossypol (20 M) for 4 h. After treatment, cells were 
immunostained for a) lysosomal marker; LAMP 1, b) mitochondria marker; HSP60. 




3.8. ERMR does not alter expression levels of mitochondrial fission and fusion 
proteins.  
MFN (mitofusin) and OPA1 (optic atrophy1) are the main regulators of the 
mitochondrial fusion31,48. The two isoforms of MFN (MFN1 and MFN2) are localized 
to the outer mitochondrial membrane, whereas OPA1 is localised to the inner 
mitochondrial membrane31. As a loss of fusion results in the proteolytic processing of 
the higher molecular weight, long isoforms (L1 and L2) of OPA1 to yield three short 
isoforms (S1-S3)48 . To check whether apogossypol-mediated ERMR regulated the 
expression levels of different mitochondrial fission-fusion proteins, cells were exposed 
with apogossypol (20 µM) for 1 h and then to CCCP (10 µM) for 1 h or A-1210477 
(20 µM) for 4 h and western blotting was carried out. In the control DMSO treated 
cells OPA1 existed as two long and three short isoforms (Figure.3.10), A-1210477 did 
not shown any alteration in OPA1 processing compared to the control (DMSO treated) 
cells. In contrast, exposure to CCCP resulted in a clear processing of the long isoforms 
of OPA1 to yield more of the short isoforms (Figure.3.10). In contrast, MFN1 and 
MFN2 protein expression levels did not change following the different treatments. 
Similarly, mitochondrial fission GTPase, DRP1 or its receptors, including MFF 
(mitochondrial fission factor), MID49 (mitochondrial dynamic protein of 49 kDa) and 
MID51 (mitochondrial dynamic protein of 51 kDa) also remained unchanged. 
Interestingly, exposure to apogossypol resulted in small decrease in the 
phosphorylation status of DRP1 (at S616, which is associated with mitochondrial 
fission) in cells exposed to either A-1210477 or CCCP. Taken together, apogossypol-
mediated ERMR does not appear to regulate the expression levels of mitochondrial 




















                                   
Figure 3.9. ERMR prevented CCCP- and A-1210477-mediated mitochondrial 
fragmentation.  HeLa cells were exposed to apogossypol (20 M) for 1 h. After pre-
treatment cells were exposed to b) CCCP (20 M) for 1 h or c) A-1210477 for 4 h. 
Cells were then co-stained with a mitochondrial marker (HSP60) and an ER tubular 
marker (RTN4). All experiments were independently performed three times. Scale bar: 
10 m. d) Quantification of CCCP- or A-1210477-mediated mitochondrial 
fragmentation was performed by counting around 100 cells, that exhibited 
mitochondrial fragmentation, from 3 independent experiments. Error bars = Mean ± 








                     
Figure 3.10. Western blot analysis of mitochondrial fission and fusion proteins. 
H1299 cells were pre-treated with apogossypol (20 M) for 1 h then treated with A-
1210477 (10 M) for 4 h or CCCP (10 M) for 1 h. After treatment, cells were lysed 









3.9. ERMR alters DRP-1 distribution  
Since DRP-1 translocation from the cytosol to mitochondrial membranes is a 
key event for mitochondrial fission27,48, it is possible that ERMR antagonises 
mitochondrial fission by preventing DRP-1 translocation. For this, cells were stained 
for endogenous DRP-1 or transfected with a DRP-1-GFP plasmid, followed by 
exposure to apogossypol (20 µM) for 4 h. Interestingly, the normal punctate 
distribution of endogenous DRP1 or overexpressed DRP-1-GFP was significantly 
altered following apogossypol-mediated ERMR (Figure.3.11). These results suggested 
that apogossypol-induced ERMR altered DRP-1 distribution. Interestingly these 
results suggested that DRP-1 is trapped within ERMR.  
            
            
Figure 3.11. ERMR effects DRP-1 distribution. a) HeLa cells were exposed to 
apogossypol (20 M) for 4 h. Cells were then co-stained with DRP-1 and an ER tubular 
marker (BAP31). b) HeLa cells were transiently transfected with wild type DRP-1-
GFP. Following transfection, the cells were exposed to apogossypol (20 M) for 4 h. 
After treatment, cells were then immunostained with ER tubular marker (BAP31). All 




3.10. ERMR antagonises BAX translocation from cytosol to mitochondria  
Previous results showed that ERMR played a crucial role on DRP1-mediated 
mitochondrial fission (Figure.3.11). DRP-1-mediated mitochondrial fission could be 
linked to apoptosis induction due to the recruitment of BAX (BCL-2 associated X 
protein) to the mitochondrial membrane with some assistance from ER 
membranes98,174,176,177. Upon apoptotic stimuli, cytosolic BAX translocates to the 
mitochondria, where it is activated to form oligomeric channels that result in 
cytochrome c release177. Therefore, to check whether the reorganised ER membranes 
would alter BAX translocation, cells were exposed to a combination of BH3 mimetics 
(A-1331852; BCL-XL inhibitor and A-1210477) in the presence of apogossypol. In 
the absence of BH3 mimetics, BAX appeared largely cytosolic (Figure.3.12), whereas 
following exposure to BH3 mimetics, BAX translocated to the mitochondrial 
membranes, characterised by its punctate staining174. Such punctate staining was 
drastically reduced in cells treated with a combination of apogossypol and BH3 
mimetics (Figure.3.12). These results demonstrated that apogossypol-mediated ERMR 
prevented the mitochondrial translocation of BAX.  
 
3.11. ERMR does not antagonise BAK activation  
In addition to BAX, BAK also has the ability to form pores on mitochondria 
membranes and eventually triggers cytochrome c release from mitochondria to 
cytosol177–179. Since ERMR prevented the mitochondrial translocation of BAX, it is 
possible for ERMR to also modulate BAK activation and pore formation. However, 
unlike BAX, BAK is generally localised within OMM and upon apoptotic stimuli, it 
undergoes conformational changes, such as the exposure of AB1 epitope, to form 
pores178. Therefore, cells were exposed to a combination of BH3 mimetics (A-
1331852; BCL XL inhibitor and A1210477; MCL-1 inhibitor) in the presence of 
apogossypol and the extent of BAK activation was measured. The punctate staining of 
BAK, which corresponds to BAK activation, was only present in cells exposed to BH3 
mimetics (Figure.3.13). Such BAK punctate were not reduced in cells treated with a 
combination of apogossypol and BH3 mimetics but mitochondrial co-localisation 





          
                  
          
 
Figure 3.12. ERMR prevented BAX translocation. a) HeLa cells were pre-treated 
with Z-VAD.fmk (30 M) for 30 min then treated with apogossypol (20 M) for 1 h.  
b) After treatment, cells were exposed to A-1210477 (10 M) + A-1331852 (0.1 M) 
for 4 h. Cells were immunostained with HSP60 and BAX antibodies. The box regions 
in the image are enlarged to show BAX localising on the mitochondria. All 




         
 
 
         
 
Figure 3.13. ERMR does not affect BAK activation. a) HeLa cells were treated with 
Z-VAD.fmk (30 M) for 30 min and then with apogossypol (20 M) for 1 h.  b) After 
treatment, cells were exposed to A-1210477 (10 M) + A-1331852 (0.1 M) for 4 h 
and immunostained with HSP60 and active-BAK antibodies. All experiments were 
independently performed three times. Scale bar: 10 m. The box regions in the image 




3.12. ERMR selectively antagonises BAX but not BAK activation  
Previous results suggested that apogossypol-mediated ERMR prevented BAX 
translocation (Figure.3.12). To check whether ERMR also prevented BAX activation, 
cells were exposed to BH3 mimetics (A-1331852; BCL XL inhibitor and A1210477; 
MCL-1 inhibitor) in the presence of apogossypol and stained with anti-BAX 6A7 
antibody. This antibody specifically recognises the α-1 helix of BAX, which is only 
exposed following apoptotic stimuli180–183. Following exposure to BH3 mimetics 
higher levels of BAX activation were determined (Figure.3.14 a). Exposure to 
apogossypol reduced BAX activation (Figure. 3.14 a), suggesting that apogossypol-
mediated ERMR prevented both BAX translocation and activation.  In agreement with 
previous results (Figure.3.12), apogossypol-mediated ERMR did not prevent BAK 
activation (Figure.3.14 b). These results confirmed that apogossypol-mediated ERMR 
preferentially prevented BAX activation but not BAK activation.  
                                                                
 
Figure 3.14. ERMR preferentially prevented BAX but not BAK activation. HeLa 
cells were exposed to apogossypol (20 M) for 1 h. Cells were exposed to A-1210477 
(10 M) + A-1331852 (0.1 M) for 4 h. Cells were stained with a) active BAX (6A7) 
antibody or b) active BAK (AB-1) antibody and, the extent of BAX and BAK 
activation assessed by flow cytometry. All experiments were independently performed 
three times. Error bars = Mean ± SEM. *** p ≤ 0.001.  
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3.13. ERMR antagonises BH3 mimetics-mediated release of cytochrome c  
Since apogossypol-mediated ERMR prevented BAX activation and 
mitochondrial translocation, it is possible that ERMR could affect BH3 mimetic-
mediated release of cytochrome c. Following exposure to a combination of BH3 
mimetics (A-1331852; BCL XL inhibitor and A1210477; MCL-1 inhibitor), an 
extensive release of cytochrome c was observed from the mitochondria to cytosol 
(Figure.3.15). Exposure to apogossypol prevented BH3 mimetic-mediated cytochrome 
c release, as observed in western blots (Figure 3.15 a and b) as well as 
immunocytochemistry (Figure 3.15 c and d). 
 








           
 
               
 
Figure 3.15. ERMR prevented cytochrome c release. HeLa cells were pre-exposed 
to Z-VAD.fmk (30 M) for 30 min and then exposed to apogossypol (20 M) for 1 h. 
Cells were exposed to A-1210477 (10 M) + A-1331852 (0.1 M) for 4 h. a) 
Quantification of extent of cytochrome c release was performed by counting ~100 
from 3 independent experiments. Error bars = Mean ± SEM. *** p ≤ 0.001. b) After 
treatment, mitochondrial and cytosolic fraction were subjected to western blot analysis 
using indicated antibodies. c) Cells were treated as before and co-stained with the 
cytochrome c and an ER tubular marker (RTN4). All experiments were independently 
performed three times. Scale bar: 10 m. 
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3.14. ERMR antagonises BH3 mimetics-mediated apoptosis in several cell lines 
Since apogossypol-mediated ERMR prevented cytochrome c release, it is 
possible that ERMR could affect BH3 mimetic-mediated apoptosis. Maver-1 (derived 
from mantle cell lymphoma) and RS 4;11 (derived from acute lymphoblastic 
leukaemia) cell lines are primarily dependent on BCL-2 for survival118,184. Exposure 
to ABT-199; BCL-2 inhibitor triggers extensive apoptosis in these cells118, which was 
prevented when exposed to a combination of apogossypol and ABT-199 (Figure.3.16 
a-b). These results suggested that apogossypol-mediated ERMR prevented ABT-199-
dependent apoptosis. Similarly, in BCL-XL dependent cell lines, KCL-22 and K562 
(chronic myeloid leukaemia cell lines), exposure to A-1331852; BCL-XL 
inhibitor118,185 triggers extensive apoptosis which was prevented in cells exposed to a 
combination of apogossypol and A-1331852 (Figure.3.16 c-d). In H929 (derived from 
multiple myeloma) primarily dependent on MCL-1 for survival, exposure to 
apogossypol prevented A-1210477-mediated apoptosis. (Figure.3.16 e). Finally, in 
H1299 (derived from non-small lung carcinoma) and HeLa (derived from cervical 
cancer) that primarily depend on both MCL-1 and BCLXL for survival, exposure to 
apogossypol prevented BH3 mimetic-mediated apoptosis (Figure.3.16 f-g). Taken 
together, these results suggested that ERMR played a significant role on BH3 mimetic-
mediated apoptosis in several cancer cell lines.  
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Figure 3.16. ERMR prevented BH3 mimetic-mediated apoptosis. a-b) BCL-2 
dependent cells (MAVER-1, RS 4;11), c-d) BCL-XL dependent cells (KCL-22, K562), 
e) MCL-1 dependent cell (H929) and f-g) BCLXL and MCL-1 dependent cells (H1299, 
HeLa) were exposed to apogossypol (20 µM) for 1 h, exposed to specific BH3 
mimetics for  4 h and assessed for apoptosis by PS externalisation. All experiments 
were independently performed three times. Error bars = Mean ± SEM. ** for p ≤ 0.005, 




3.15. Different pharmacological agents showing extensive ERMR also prevents 
BH3 mimetic-mediated apoptosis.  
Since apogossypol is capable of inducing ERMR as well as preventing BH3 
mimetic-mediated apoptosis, it is important to assess whether the anti-apoptotic effect 
of apogossypol was due to its ability to induce ERMR.  
Previously reports have identified other structurally diverse compounds that also 
induced ERMR90,91 . It is possible that these compounds could also prevent BH3 
mimetic-mediated apoptosis. Therefore, to investigate this, cells were exposed to 
structurally diverse reorganisation inducers, such as NDGA (antioxidant), ivermectin 
(anthelmintic), terfenadine (antihistamine) and suloctidil (vasodilator). All compounds 
induced ERMR, with suloctidil being the least efficient compared to the other three 
compounds (Figure.3.17 a,b). In agreement, the protective effect of the different 
compounds mimicked their ability to induce ER membrane reorganisation 
(Figure.3.17 b), thus probably explaining why suloctidil was not as potent as the other 
agents in protecting against BH3 mimetics mediated apoptosis. However, we cannot 
exclude the possibility that suloctidil might have its off-target effect on anti-apoptotic 
function. Overall, our data demonstrated that ERMR antagonised mitochondrial 
fission and BH3 mimetic-mediated apoptosis. 
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Figure 3.17. Other ERMR inducers induced ERMR and antagonised BH3 
mimetic-mediated apoptosis. a) HeLa cells were pre-treated with NDGA (50 M), 
ivermectin (20 M), terfenadine (5 M) or suloctidil (5 M) for 4 h. The cells were 
then immunostained for an ER tubule markers (BAP31). b) Quantification of extent of 
ERMR was performed by counting around 100 cells from 3 independent experiments. 
Error bars = Mean ± SEM. ** for p ≤ 0.005, *** p ≤ 0.001. c) Cells were exposed to 
indicated ERMR inducers for 1 h followed by a combination of A-1210477 (10 µM) 




3.16. Discussion  
ER-mitochondria contacts have been previously shown to play important roles 
in calcium signalling, mitochondrial structural dynamics and apoptosis7,48. Growing 
evidence suggests that ER tubules regulate mitochondrial fission by physically 
wrapping around the mitochondria for initiating mitochondrial constriction, which is 
followed by the recruitment of DRP-1 onto the constriction sites. Thus, recruited DRP-
1 further undergoes conformational changes to finally result in mitochondrial 
fission27,48,186. These events are also linked to cell fate decisions, including autophagy 
and apoptosis92,187,188. Understanding the impact of ER-mitochondria interactions on 
apoptosis is essential to improve cancer therapy, as most of the anti-cancer agents kill 
cancer cells through the mitochondrial apoptotic pathway. Since mitochondria are 
closely associated with the ER for maintaining their structural dynamics and important 
physiological functions, it is possible that disrupting this association may alter 
mitochondrial structural dynamics and functional homeostasis. One way to achieve 
this is by remodelling ER structure using inducers of ER membrane reorganisation 
(ERMR)90,91 (Figure 3.1).  
Initial characterisation of ERMR study focused on investigating the domains 
within ER that contributed to ERMR. It is well known that ER appears as different 
structural domains. These include the elongated and filamentous ER tubules as well as 
the flattened ER sheets. Previous studies demonstrated that proteins that reside in ER 
tubules such as, RTN4 (reticulon-4)91 and BAP31 (B- cell receptor associated protein 
of 31KDa)156 colocalised with ERMR (Figure 3.3 and 3.4). In this study, using two 
marker proteins that reside in ER sheets, namely  CLIMP-63 (cytoskeleton linking 
membrane protein 63) and kinectin-1 (KNT-1) (Figure 3.5) , it has been convincingly 
shown that ERMR is almost exclusively from ER tubules and ER sheet proteins do not 
contribute to these structures (Figure 3.4 and 3.5). In addition, ER also have luminal 
spaces, which are responsible for creating a suitable environment for important cellular 
process, including protein synthesis and folding. Chaperones, such as BIP189 (binding 
protein) and PDI (protein disulphide isomerase)190 reside in the lumen and regulate 
protein folding163. This study demonstrates that apogossypol-induced ERMR is 
restricted to ER tubular proteins but not lumenal proteins (Figure 3.6). Since ER 
tubules and sheets are interconnected and may share continuous luminal space, it is 
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hard to speculate why the lumenal space is not involved in the ERMR.  It is possible 
that ER lumen may be compartmentalised within specific regions of the ER tubules 
and all of ER sheets. Therefore, regions that form ERMR may not have the lumenal 
space/ proteins, thus forming compact membranous bundles. Even at the level of 
electron microscopy, the reorganised ER bundles appear to be largely devoid of lumen. 
Moreover, the fact that the UPR occurs exclusively at ER lumen and that ERMR is 
distinct from the UPR adds further support to this theory. This can be proved 
definitively by either performing high resolution confocal microscopy or correlative 
immunogold labelling studies. 
Although ERMR colocalised with ER tubule markers, the reorganised 
membranes do not seem to share membranes from other subcellular organelles, 
including the Golgi complex, lysosomes and mitochondria (Figures 3.7 and 3.8). 
However, Golgi complex seems to be dispersed upon exposure to apogossypol, in 
agreement with previous work91. Dispersed Golgi is the one of the hallmarks for 
ERMR and indicates defective ER-Golgi vesicular trafficking91. Unlike Golgi, ERMR 
does not seem to alter the structure of lysosomes and mitochondria, despite sharing 
close contacts with these organelles. Therefore, initial studies suggested that ERMR 
may not influence mitochondrial or lysosomal structure. This was because 
mitochondria appeared filamentous in both control (DMSO-treated) as well as 
apogossypol-treated cells (Figure 3.8). However, recent reports suggest that ER 
tubules play an important role on regulating mitochondrial fission by physically 
wrapping around mitochondria and marking constriction sites7,91. In agreement, 
apogossypol-mediated ERMR prevented CCCP- and BH3 mimetic-mediated 
mitochondrial fission (Figure 3.9). These results suggested that ERMR altered 
mitochondrial membrane dynamics, which was evident only when cells were exposed 
to mitochondrial fission inducers. Such an effect was not observed in control cells, 
possibly because in HeLa and H1299 cell lines, mitochondria are already hyper 
filamentous. So, the effect of apogossypol to further enhance fusion was not clear. This 
can of course be overcome by using cells, such as MCF7, which generally have 
fragmented mitochondrial network. 
It has been reported that CCCP- and A-1210477-mediated mitochondrial 
fission were strongly dependent on DRP-1174. Normally, DRP-1 resides within the 
cytosol, and upon fission, translocates to the mitochondria to induce mitochondrial 
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fission. The effect of apogossypol to prevent mitochondrial fission might be due to the 
inability of DRP-1 to translocate to the mitochondrial fission site. This was evident by 
the sequestration of DRP-1 within the reorganised ER membranes (Figure 3.11). 
Therefore, this suggests that DRP-1 is possibly localised to specific regions within ER, 
which upon fission stimuli, gets translocated to mitochondrial membranes while the 
ER wraps around the construction site. This could not be proved by confocal 
microscopy. Solid conclusions can be drawn only following subcellular fractionation 
to isolate mitochondrial, cytosol and ER fractions. Efforts to perform this study were 
largely unsuccessful due to technical reasons. 
During fission DRP-1 translocated to mitochondria and coupled with its 
receptors, MFF, MiD49, and MiD5 which reside on mitochondrial fission sites to 
facilitate mitochondrial fission31,51,191. Although ERMR does not change the proteins 
expression levels of DRP-1 or its receptors, ERMR appears to alter the 
phosphorylation status of DRP-1. It has been reported that phosphorylation at serine 
616 (pDRP1 S616) is associated with mitochondrial fission48,192, whereas 
phosphorylation at serine 637 (pDRP1 S637) is associated with mitochondrial 
fusion48,193,194. This was more promising in cells exposed to CCCP and A-120477, 
which resulted in an increase in serine 616 phosphorylated DRP-1 that was 
antagonised by apogossypol (Figure 3.10). These results suggested that apogossypol-
mediated ERMR could be regulating DRP-1 S616 phosphorylation. On the contrary, 
exposure to CCCP also increased serine 637 phosphorylation of DRP-1, which 
decreased when cells were also exposed to apogossypol (Figure 3.10). Although this 
was not observed following BH3 mimetics, these findings were counterintuitive. 
Further studies will have to be carried out in this area, as these preliminary findings 
suggest that apogossypol-mediated ERMR may be regulating mitochondrial fission 
through a complex mechanism. 
This was more apparent with OPA1 protein levels, as this mitochondrial fusion 
protein has been shown to exist as different isoforms48,108, and upon fission, undergoes 
proteolysis during which the long isoforms (L1 and L2) of OPA1 are cleaved into three 
short isoforms (S1, S2 and S3)195. In agreement, a mitochondrial fission inducer 
(CCCP) cleaved the long OPA1 isoforms into more shorter isoforms (Figure.3.10), 
such proteolytic cleavage was not reversed in cells exposed to apogossypol. In fact, 
apogossypol alone appeared to induce OPA1 proteolysis in cells. Taken together, these 
71 
 
results suggested that apogossypol-mediated ERMR plays a complex role in OPA1 
proteolysis and mitochondrial membrane dynamics. 
Since ERMR altered DRP-1 distribution, it is possible that ERMR might also 
alter BAX translocation, as DRP-1 and BAX have been shown to interact at the 
constriction sites48. This study demonstrates that ERMR specifically prevented BAX, 
but not BAK, activation and translocation to outer mitochondrial membrane (Figure 
3.12). Although, HeLa cells express both BAX and BAK, it is unclear as to why these 
cells do not undergo apoptosis even when BAK is fully active in the presence of 
apogossypol. Clearly, in this study, HeLa cells appear to rely only on BAX and not 
BAK for apoptosis induction. This is not surprising as BH3 mimetic-mediated 
apoptosis seem to depend almost exclusively on BAX. Therefore, it is possible that 
unless BAX is available, active BAK cannot initiate apoptosis, at least under this 
condition. Further studies in a panel of cell lines will have to performed to better 
understand this phenomenon. 
Collectively, this study demonstrates the ability of apogossypol-mediated 
ERMR to antagonise BH3 mimetic-mediated mitochondrial fission, BAX 
translocation, cytochrome c release and apoptosis (Figure 3.18). Although the 
experiments carried out with other ERMR inducers are largely in agreement with the 
effects of apogossypol-mediated ERMR, it is hard to uncouple the anti-apoptotic 
effects of apogossypol from those of ERMR. Therefore, the next results chapter will 
be aimed at uncoupling these events to prove that the anti-apoptotic effects are indeed 


















Figure 3.18. Schematic representation of the mitochondrial changes regulated by 
ERMR. Generally, ER and mitochondria are closely associated with each other and 
these interactions are extremely important for cellular homeostasis, bioenergetics and 
cell survival. ER tubules achieve these by wrapping around mitochondria and 
facilitating DRP-1-mediated mitochondrial fission. Apoptotic stimuli cause BAX 
translocation on mitochondrial membranes to trigger cytochrome c release and 
apoptosis. Apogossypol-induced ERMR disrupts such communication between ER 
and mitochondria, decreasing mitochondrial fission, BAX translocation, cytochrome 









4.Chapter 4  
DHODH modulates both ERMR and 
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4.1. Background   
Since ERMR appears to regulate important physiological functions, like 
mitochondrial fission and apoptosis (Chapter 3), it is important to understand the 
initiation process of ERMR to uncouple the effects of apogossypol from ERMR in 
these functions. ER is widely extended throughout the cells and responsible for 
regulating various physiological functions, including calcium signalling70,71,196, 
protein folding197 and lipid synthesis21,25,31,33,47,168,198. It has been reported that ER 
becomes reorganised upon exposure to apogossypol91,199, as well as several other 
agents that target calcium homeostasis90. Intracellular calcium stores ar maintained by 
several pumps, including the sarco/endoplasmic reticulum calcium ATP ases 
(SERCA), which facilitates calcium influx into the ER lumen25,26. Impairment or 
inhibition of SERCA activity prevents calcium influx to the ER lumen and depletes 
ER calcium stores52,200–202. Depleted ER calcium stores initiates an adaptive signalling 
and invokes the store operated calcium entry (SOCE) to refill ER lumenal 
calcium21,25,26. SOCE is mediated by ER resident proteins, STIM1 (stromal interaction 
molecule 1) and STIM2 (stromal interaction molecule 2). Both these proteins act as 
calcium sensors to detect reduced ER lumenal calcium store and helps to refill emptied 
ER calcium stores, through coupling with specific plasma membrane calcium channel 
proteins, such as ORAI1, ORAI2 and ORAI3 (calcium release-activated calcium 
channel protein 1,2 and 3)45,46. The interaction between STIMs and ORAI is crucial 
for maintaining calcium homeostasis201,202.  
It has been reported that overexpressed STIM1 can induce ERMR90,91 . 
Moreover, apogossypol-mediated ERMR has been associated with SOCE 90, and 2-
APB (2-aminoethoxydiphenyl borate), an inhibitor for SOCE, can efficiently prevent 
apogossypol-mediated ERMR90. These findings suggested there could be specific 
regulatory mechanisms between STIM and SOCE that could modulate ERMR. 
However, a previous study suggested that silencing the expression levels of SOCE 
regulators (STIM1, ORAI1 and STIM1) does not alter apogossypol-mediated ERMR90 
. In addition, extracellular supplementation of calcium also does not alter ERMR, 
further suggesting that 2-APB most likely regulated ERMR independent of calcium 
signalling. Nevertheless, 2-APB could be an important tool to identify whether the 






Figure 4.1 Schematic representation of regulatory process of apogossypol-
induced ERMR. Under normal conditions, ER is spread throughout the cell and 
functions in maintaining calcium homeostasis. Exposure to thapsigargin (THG) 
inhibits SERCA ATPase, which depletes ER calcium, thus driving STIM1/2 and 
ORAI1/2/3-mediated store-operated calcium influx into the cell. 2-APB inhibits this 
calcium influx but also prevents apogossypol-mediated ERMR. (Scheme adapted from 





Recently, Rhaman et al203 examined a large panel of FDA approved drugs to 
identify specific SOCE inhibitors. Their study found that inhibitors of DHODH, such 
as teriflunomide and leflunomide, were strong modulators of SOCE. Therefore, in this 
chapter, the experiments will examine whether these agents would prevent 
apogossypol-mediated ERMR, thus uncoupling the protective effects of ERMR from 
apogossypol. Since the primary function of teriflunomide and leflunomide is to 
modulate the de novo pyrimidine biosynthesis via inhibition of enzyme DHODH 
(dihydroorotate dehydrogenase)133,136,140,204, experiments in this chapter will focus on 
addressing the following questions: 
(1) Can the SOCE inhibitors abolish apogossypol-mediated ERMR and revert the anti-
apoptotic effects of ERMR? 




4.2. 2-APB prevents apogossypol-mediated ERMR   
It has been reported that 2-APB, an inhibitor of SOCE, is capable of diminishing 
apogossypol-mediated ERMR. It is possible that 2-APB-mediated decrease in ERMR 
could also abolish the anti-apoptotic functions of ERMR. Therefore, to check this, cells 
were exposed to increasing concentrations of 2-APB for 1 hr and treated with 
apogossypol (20 µM) for 4 h. It must be noted that cells were exposed to 2-APB 
throughout the course of this experiment. Then, ERMR was assessed using confocal 
microscopy. In agreement with previous findings, 2-APB prevented apogossypol-
mediated ERMR in a concentration- dependent manner (Figure 4.2). In addition, the 
minimum concentration of 2-APB required to abolish ERMR was 100 µM (Figure 





Figure 4.2 2-APB prevents apogossypol-mediated ERMR. HeLa cells were 
exposed with indicated concentrations of 2-APB for 1 h and treated with apogossypol 
(20 M) for 4 h. The cells were then immunostained for ER tubule marker BAP31. All 








4.3. High concentration of 2-APB is cytotoxic to cells  
Since 2-APB abolishes apogossypol-mediated ERMR, it is possible that 2-APB 
could also reverse the anti-apoptotic functions of ERMR. To test this possibility, cells 
were exposed to 2-APB (100 µM) for 1 h, in the presence of apogossypol (20 µM) and 
BH3 mimetics (A-1331852; BCL XL inhibitor and A1210477; MCL-1 inhibitor) for 4 
h. The ability of apogossypol to antagonise BH3 mimetic-mediated apoptosis, in the 
presence of 2-APB, was then assessed by flow cytometry. While BH3 mimetics 
induced extensive apoptosis, apogossypol diminished the extent of apoptosis, in 
agreement with previous findings (Figures 3.17 and 4.3). However, 2-APB as a single 
agent induced extensive apoptosis, which further enhanced cell death in the presence 
of BH3 mimetics and apogossypol (Figure 4.3 b). Taken together, these results 
suggested that 2-APB, whilst suitable to modulate ERMR, was not useful to study the 




4.4. Leflunomide and teriflunomide prevent apogossypol-mediated ERMR      
   Since 2-APB could not be used to study the anti-apoptotic functions of ERMR, 
there was a need to find alternative tools to study these functions. A recent study by 
Rhaman et al203 examined a large panel of FDA-approved drugs to identify specific 
SOCE inhibitors and concluded that leflunomide and teriflunomide could potentially 
inhibit SOCE. Since 2-APB prevented apogossypol-mediated ERMR, most likely via 
its ability to inhibit SOCE, it is possible that leflunomide and teriflunomide could also 
prevent apogossypol-mediated ERMR. To test this, cells were exposed to increasing 
concentrations of leflunomide or teriflunomide (0 − 200 M) for 1 h and then exposed 
to apogossypol (20 M) for 4 h. Both leflunomide and teriflunomide abolish 
apogossypol-mediated ERMR in a concentration-dependent manner (Figures 4.4 and 
4.5). The minimum concentration of leflunomide and teriflunomide required to abolish 





              
 
 
    
             
 
Figure 4.3  2-APB induces apoptosis. HeLa cells were exposed to 2-APB (100 µM) 
for 1 h, then exposed to apogossypol (20 µM) for 1 h and finally exposed to A-1210477 
(10 µM) and A-1331852 (0.1 µM) for 4 h. After treatment, cells were assessed for 
apoptosis by PS externalisation. All experiments were independently performed three 














                                          
Figure 4.4 Leflunomide abolishes apogossypol-mediated ERMR. a) HeLa cells 
were exposed to indicated concentrations of leflunomide for 1 h and then exposed to 
apogossypol (20 M) for 4 h. The cells were then immunostained for an ER tubule 
marker (BAP31). Scale bar: 10 m. b) Quantification of ER membrane reorganisation 
was performed by counting around 100 cells from 3 independent experiments. Error 
















                          
Figure 4.5 Teriflunomide reduces apogossypol-mediated ERMR. a) HeLa cells 
were exposed to indicated concentrations of teriflunomide for 1 h and then exposed to 
apogossypol (20 M) for 4 h. The cells were then immunostained for an ER tubule 
marker (BAP31). Scale bar: 10 m. b) Quantification of ER membrane reorganisation 
was performed by counting around 100 cells from 3 independent experiments. Error 






4.5. DHODH inhibitors alone does not change ER morphology  
Although both leflunomide and teriflunomide abolished apogossypol-mediated 
ERMR, it was necessary to assess if these inhibitors altered ER morphology thus 
inducing ERMR on their own. In both untreated (DMSO) and treated cells, increasing 
concentrations of leflunomide and teriflunomide did not result in any marked changes 
to ER morphology (Figure 4.6).  
 
4.6. DHODH inhibitors induce the UPR in a concentration-and time-
dependent manner  
It has been reported that DHODH inhibitors induce canonical ER stress and the 
UPR79,205. The UPR is an adaptive response signalling pathway regulated via three 
different stress sensors including inositol-requiring enzyme 1 (IRE1), activating 
transcription factor 6 (ATF6) and protein kinase RNA-like ER kinase (PERK). Upon 
ER stress, BiP dissociates from these stress sensors and these eventually activate the 
adaptive UPR signalling to maintain ER homeostasis. Prolonged ER stress is unable 
to maintain such ER homeostasis, and as a result, induces apoptosis via upregulation 
of CHOP (CCAAT/enhancer-binding protein homologous protein; a transcription 
factor)5,79,163,206. Since both BiP and CHOP play important roles in ER stress 
signalling, these are widely used as ER stress markers79. Chemical agents like 
tunicamycin (TU), induce extensive ER stress and as a result are commonly used as 
positive controls to induce ER stress197,207,208. To check whether DHODH inhibitors 
induce ER stress and the UPR, cells were exposed to increased concentrations of both 
teriflunomide and leflunomide and protein levels of BiP and CHOP assessed by 
western blotting. At concentrations higher than 200 M, teriflunomide induces 
upregulation of both BiP and CHOP (Figure 4.7 a). Upregulation of BiP was not too 
edvident in cells exposed to leflunomide, but a drastic increase in CHOP levels were 
observed at concentrations as low as 50 M (Figure 4.7 a). Induction of CHOP but not 
BiP were observed when cells were exposed to leflunomide (200 M), as early as 4 h 
(Figure 4.7 b). However, this was not evident in cells exposed to this concentration 





























Figure 4.6. Teriflunomide and leflunomide compounds alone do not induce ER 
membrane reorganisation. HeLa cells were exposed with indicated concentration of 
DHODH inhibitors including teriflunomide or leflunomide for 1 h then treated with 
apogossypol (20 M) for 4 h. The cells were then immunostained for ER tubule marker 











Figure 4.7 Teriflunomide and leflunomide induces UPR in a concentration- and 
time-dependent manner. a) HeLa cells were exposed to indicated concentrations of 
teriflunomide and leflunomide for 24 h or b) to fixed concentrations of teriflunomide 
(200 M) or leflunomide (200 M) for the indicated times. After treatment, cells were 
lysed and subjected to western blot analysis using the indicated antibodies. Conc= 







4.7. DHODH inhibitors trigger apoptosis in a concentration and time-
dependent manner  
To evaluate whether DHODH inhibitors induce apoptosis, cells were exposed to 
increasing concentration of inhibitors for 24 and 48 h. Both DHODH inhibitors 
induced apoptosis in a concentration- and time-dependent manner (Figure 4.8). 
                                                         
         
                                                                       
         
Figure 4.8 DHODH inhibitors induce apotosis in a concentration- and time-
dependent manner. HeLa cells were treated with indicated concentrations of 
DHODH inhibitors for (a and c) 24 h and (b and d) 48 h and assessed for PS 
externalisation. All experiments were independently performed three times. Error bars 




4.8. DHODH does not play crucial role in apogossypol-mediated-ERMR  
Several studies suggest that leflunomide and teriflunomide modulate de novo 
pyrimidine biosynthesis via inhibition of the DHODH enzyme127,128,137. To confirm 
that leflunomide and teriflunomide abolish apogossypol-mediated ERMR by 
inhibiting DHODH, cells were transiently transfected with two different DHODH 
siRNAs and then treated with apogossypol. Results showed that silencing the 
expression levels of DHODH did not affect apogossypol-mediated ERMR (Figure 
4.9a). In addition, quantification was performed by counting around 100 cells from 3 
independent experiments (Figure 4.9b). The knockdown efficiency of DHODH 
siRNAs was verified by western blotting from 3 independent experiments (Figure 
4.9c). DHODH protein expression levels were marginally reduced following DHODH 
siRNAs, which was evident from the densitometry analysis that showed that, ~ 40% 
of DHODH protein expression was reduced following different siRNAs (Figure 4.9d). 
However, despite this reduction in expression levels, apogossypol-mediated ERMR 








                      
                          
                                                                 
                    
 
Figure 4.9 DHODH does not play a crucial role in regulating apogossypol-
mediated ERMR. a) HeLa cells were transiently transfected with either control 
siRNA or two different DHODH siRNAs and then exposed to apogossypol (20 M) 
for 4 h. The cells were then immunostained with an ER tubule marker (BAP31). Scale 
bar 10 m. b) Quantification of ER membrane reorganisation was performed by 
counting around 100 cells from 3 independent experiments. c) Knockdown efficiency 
was tested using western blotting. d) Densitometric quantification of DHODH protein 
versus GAPDH. Error bars = Mean ± SEM. ** p ≤ 0.005, *** p ≤ 0.001. 
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4.9. Metabolic supplementation of orotate or uridine does not alter 
apogossypol-mediated ERMR 
Although the genetic downregulation of DHODH failed to prevent apogossypol-
mediated ERMR, it is possible that the residual DHODH (owing to inefficient 
knockdowns) may still be responsible for the lack of prevention. Therefore, to 
convincingly rule out an involvement of DHODH in this process, intermediates of 
pyrimidine synthesis, such as orotate and uridine123–125 were utilised in the 
experiments. Orotate is the product of DHODH and orotate is further converted to 
urdine/ UMP in the presence of UMP synthetase. Cells exposed to orotate or uridine, 
in the presence of teriflunomide and leflunomide as well as apogossypol still resulted 
in a significant block in apogossypol-mediated ERMR, which was unaffected by 
orotate or uridine supplementation (Figures 4.10 and 4.11). Together, these results 
strongly suggested that teriflunomide and leflunomide mediated anti-ERMR effect 
most likely via a DHODH-independent manner. 
 
4.10. Teriflunomide restores apoptosis antagonised by ERMR   
Since, apogossypol prevented BH3 mimetic-mediated apoptosis and 
teriflunomide prevented apogossypol-mediated ERMR, it is possible that 
teriflunomide could antagonise the anti-apoptotic effect of ERMR. To test this, cells 
were exposed to teriflunomide (200 M) for 1 h and then exposed to apogossypol (20 
M) for 1 h. Finally, cells were exposed to a combination of A-1210477 (10 M) and 
A-1331852 (0.1 M) for 4 h and apoptosis assessed by PS externalisation by flow 
cytometry. Cells pre-exposed to teriflunomide reversed the anti-apoptotic effects of 
apogossypol-mediated ERMR on BH3 mimetic-mediated apoptosis (Figure 4.12). In 
cells exposed to BH3 mimetics, PARP, caspases-9, caspase-3 and caspase-7 were 
processed (Figure 4.12). Apogossypol prevented this activation, which was efficiently 





                
 
 
                                        
Figure 4.10 Orotate does not alter apogossypol-mediated ERMR. a) HeLa cells 
were exposed to orotate (1 mM) for 1 h and treated with leflunomide (200 M) or 
teriflunomide (200 M) for 1 h. After treatment, cells were exposed to apogossypol 
(20 M) for 4 h. The cells were then immunostained for an ER tubule marker (BAP31). 
All experiments were independently performed three times. Scale bar: 10 m. b) 
Quantification of ERMR was performed by counting around 100 cells from 3 




     
  
                                               
Figure 4.11 Uridine does not alter apogossypol-mediated ERMR. a) HeLa cells 
were exposed to uridine (1 mM) for 1h and then treated with leflunomide (200 M) or 
teriflunomide (200 M) for 1 h. After that, cells were exposed to apogossypol (20 M) 
for 4 h. The cells were then immunostained for an ER tubule marker (BAP31). All 
experiments were independently performed three times. Scale bar: 10 m. b) 
Quantification of ERMR was performed by counting around 100 cells from 3 








                                     
Figure 4.12 Teriflunomide restores apoptosis antagonised by ERMR. HeLa cells 
were exposed to teriflunomide (200 M) for 1 h and then treated with apogossypol (20 
M) for 1 h. After treatment, cells were exposed to A-1210477 (10 M) and A-
1331852 (0.1 M) for 4 h. a) Images were acquired using FLoid® cell imaging station. 
Scale bar: 2 m. b) Following treatment, cells were stained with annexin V and PI, 
and the extent of apoptosis was measured by flow cytometry. All experiments were 
independently performed three times. Error bars = Mean ± SEM. *** p ≤ 0.001.  
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Figure 4.13 Teriflunomide restores apoptosis antagonised by ERMR. HeLa cells 
were exposed to teriflunomide (200 M) for 1 h and then treated with apogossypol (20 
M) for 1 h. After treatment, cells were exposed to A-1210477 (10 M) and A-
1331852 (0.1 M) for 4 h. Following treatment, cells were lysed and subjected to 
western blot analysis using the indicated antibodies. All experiments were 
independently performed three times. Densitometric quantification of indicated 
proteins versus GAPDH. Error bars = Mean ± SEM. ** p ≤ 0.005, *** p ≤ 0.001.  
94 
 
4.11. Discussion  
Data from the first results chapter demonstrated that apogossypol-mediated 
ERMR played a regulatory role in mitochondrial fission and apoptosis (Chapter 3). To 
ensure that the protective effects are due to ERMR and not due to a non-specific effect 
of apogossypol, modulators of ERMR were used in this chapter to study their roles in 
BH3 mimetic-mediated apoptosis.  
Since 2-APB (SOCE inhibitor) extensively prevented apogossypol-mediated 
ERMR11, experiments were performed to assess their effects on apoptosis. However, 
at concentrations enough to antagonise ERMR, 2-APB was toxic to the cells. This 
could be because 2-APB is not a specific inhibitor of SOCE. It must be noted that 2-
APB has been shown to modulate calcium signalling even at lower concentrations (10-
20 µM). Therefore, toxicity associated with a high concentration of 2-APB is most 
likely due to its non-specific effects that are largely independent of SOCE. This is 
further strengthened by previous reports in which, silencing the expression levels of 
SOCE regulators, such as STIM1, ORAI1 and ORAI3 had no effect on apogossypol-
mediated ERMR90. It has been reported that 2-APB can modulate inositol 1,4,5-
trisphosphate (IP3) channels
209,210. They are ER calcium efflux channels located on ER 
membranes and they help in maintaining ER homeostasis52. Silencing all three 
isoforms of IP3 receptors does not alter apogossypol-mediated ERMR, suggesting that 
these receptors are not the primary site of action for 2-APB. 
Although the current data argues for a SOCE-independent role for 2-APB in 
antagonising ERMR, two other SOCE modulators, teriflunomide and leflunomide 
were able to prevent apogossypol-mediated ERMR in a concentration-dependent 
manner (Figure 4.4 and 4.5).  In addition, these agents do not alter ER structure, when 
used as single agents (Figure 4.6). These findings suggest that teriflunomide and 
leflunomide alter ERMR without perturbing normal ER morphology. Leflunomide 
was more potent than teriflunomide in preventing apogossypol-mediated ERMR 
(Figure 4.4 and 4.5). This was surprising because leflunomide is a pro-drug that gets 
converted to its active metabolite, teriflunomide128,143. Subsequently, teriflunomide 
can potently inhibit the activity of DHODH. So, for a more potent DHODH inhibitor 
to have a lesser effect on preventing ERMR, it must mean that the activity of 
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leflunomide was most likely independent of its ability to inhibit DHODH or toxicity 
associated with these inhibitors might be preventing ERMR. 
DHODH inhibitors have been shown to induce canonical ER stress and the 
UPR79,205, which could be confirmed in the current chapter (Figure 4.7). In addition, 
DHDOH inhibitor exposed cells induces canonical ER stress and UPR at later time 
points (more than 12 h required) and at higher concentration (more than 500 µM 
required). Since DHODH inhibitors prevented apogossypol-mediated ERMR within 4 
h, at 200 µM concentration suggested that these DHODH mediated anti-ERMR effect 
regulated independent of UPR.  
To assess the function of DHODH in ERMR regulation, DHODH protein 
levels were reduced following DHODH siRNAs, which failed to modulate 
apogossypol-mediated ERMR (Figure 4.9). This suggested that DHODH had no role 
to play in ERMR. However, densitometry analysis of the siRNA blots showed that 
only ~ 40% of DHODH protein expression was reduced following the different 
siRNAs. Therefore, it is premature to exclude a role for DHODH in the regulation of 
ERMR. Further studies aimed at a complete knockdown of DHDOH, possibly using 
CRISPR (clustered regularly interspaced short palindromic repeats), could offer more 
insights into this phenomenon. However, DHODH plays a vital role in cell survival, 
complete silencing of DHODH will certainly be toxic to the cells.  DHODH catalyses 
the fourth step in the de novo pyrimidine biosynthesis converting dihydroorotate to 
orotate, which eventually forms uridine mono phosphate (UMP)123,125. Metabolic 
supplementation of cells with orotate or uridine must thus overcome the effect of 
DHODH inhibition. The results presented in this chapter demonstrate that neither 
orotate nor uridine supplementation altered apogossypol-mediated ERMR suggesting 
that teriflunomide/leflunomide-mediated anti-ERMR effect might be independent of 
DHODH.  The appropriate concentrations of orotate and uridine were determined by 
an independent experiment that will be discussed later in this thesis in chapter 6. 
The major findings from this chapter include the reversal of the anti-apoptotic 
effects of ERMR by teriflunomide and leflunomide, which appear to exert their effects 
in a DHODH independent manner (Figure 4.12 and 4.14). Having established a novel 
role for DHODH inhibitors in membrane dynamics, the next chapter will focus on 









Figure 4.14 Schematic representation of the mitochondrial changes regulated by 
ERMR. Apogosspypol-mediated ERMR antagonises BH3 mimetic-mediated 
apoptosis at the level of mitochondrial fission and BAX translocation. Inhibitors of 
DHODH, teriflunomide and leflunomide, prevent apogossypol-mediated ERMR via 
an unknown mechanism that is independent of DHODH enzyme activity. By 
antagonising apogossypol-mediated ERMR, teriflunomide also reverts the anti-
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5.1. Background   
DHODH inhibitors play a critical role in the regulation of ER membrane 
dynamics211, which appears to regulate mitochondrial fission and apoptosis (Chapter 
4). In addition, growing evidence suggests that DHODH inhibitors act as tools for 
cancer therapy126,128,132. These drugs are under investigation for the treatment of acute 
myeloid leukemia (AML), triple-negative breast cancer (TNBC) therapy, prostate 
cancer, colon cancer and oral squamous cell carcinoma212–214.  DHODH is an important 
enzyme in the de novo pyrimidine biosynthesis pathway. It is responsible for 
converting dihydroorotate to orotate, which eventually converts to uridine 
monophosphate (UMP) in presence of UMP synthetase125,127. 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common 
cancer types worldwide215–219, including the United Kingdom (UK). The incidence of 
HNSCC in Liverpool is four times the national average215–217. HNSCC is often 
detected in different head and neck regions, including oral cavity (OC), larynx (LX), 
oropharynx (OP) and hypopharynx (HP)215. HNSCC malignancy is highly associated 
with different risk factors, including tobacco usage and alcohol consumption215. 
Currently, HNSCC is treated either with surgery, radiation or chemotherapy218,219. A 
combination therapy, involving surgery, followed by radiation therapy or 
chemotherapy is commonly used. Although the current therapies are promising, many 
patients are prone to develop tumour recurrence and distant metastasis215. In addition, 
these therapeutics frequently cause changes in speech, swallowing, which eventually 
affects the patient’s quality of life and ability to function in society219. Therefore, there 
is a need for improved therapies. Since DHODH inhibitors act as antitumor agents in 
several cancers, DHODH could be potential candidate for HNSCC therapy.  
 DHODH is chemically inhibited by several agents, including brequinar, 
leflunomide, teriflunomide, Bayer (BAY2402234) and ASLAN003 (Figure 
5.2)127,129,137,138. Brequinar was developed in the mid 1980’s and tested in a number of 
cancers, including head and neck cancer137,142. Reports suggested that brequinar has 
not shown significant effect on early phase clinical trials of head and neck141,142, 
breast212 and ovarian cancer214. Leflunomide (Arava) was later designed against 
DHODH for treating rheumatoid arthritis and this drug successfully gained FDA 
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approval in 1999145,146,220. Several findings report that leflunomide has a short  half-
life and its treatment often causes severe liver toxicity within 6 months143. Due to liver 
toxicity and weak potency, leflunomide was structurally modified to obtain 
teriflunomide146. Teriflunomide is the active derivative of leflunomide and the only 
difference between these two drugs is the opening of the isoxazole ring (Figure 5.1). 
Upon oral administration, the isoxazole ring of leflunomide opens and teriflunomide 
is formed146.  
 
         
 
 Figure 5.1. chemical structures and conversion of leflunomide to teriflunomide. 
 
Teriflunomide was successfully investigated in clinical trials and received FDA 
approval in 2012. Since teriflunomide is actively used as a therapeutic agent for 
treating different cancers, it is used as the primary investigation tool for this study.  
The specific questions that will be addressed in this chapter are as follows:  
(1) Do the genetic and chemical inhibition of DHODH alter HNSCC cell survival?  
(2) Could the pyrimidine intermediates control DHODH-mediated survival effect? 
(3) Do DHODH inhibitors demonstrate synergy with current chemotherapeutic 





















5.2. DHODH expression in several HNSCC cells.   
Since DHODH plays an essential role in ERMR and de novo pyrimidine 
synthesis, it is possible that DHODH may regulate cancer cell survival. To understand 
the role of DHODH in HNSCC, western blot analysis was performed to check 
DHODH levels in several HNSCC cell lines. For this, whole cell lysates of UMSCC-
1 (derived from oral cavity), UMSCC-11B (derived from larynx), UMSCC-81B 
(derived from oropharynx) and FaDu (derived from hypopharynx) were collected and 
subjected to western blot using DHODH antibody. The results indicate that DHODH 
is highly expressed in several HNSCC cells (Figure 5.3).  Since it is highly expressed 
in several HNSCC cells, DHODH may be useful as a therapeutic target in HNSCC. 
 
 
             
 
Figure 5.3. DHODH is highly expressed in different HNSCC cells. The indicated 
cell lines were lysed and subjected to western blot analysis using the DHODH 






5.3. DHODH expression is critical for the clonogenic survival of cell lines 
derived from oral cavity and larynx 
To assess if DHODH expression is important for HNSCC cell survival, cell lines 
derived from oral cavity and larynx were transiently transfected with either control 
siRNA or two different DHODH siRNAs, and clonogenic assay was performed. The 
results of this assay revealed that the colony numbers and sizes were largely reduced 
upon silencing of DHODH (Figure 5.4), suggesting that DHODH expression is 
essential for clonogenic survival in these cancer cells.   
  
 
                                            
Figure 5.4. DHODH expression is critical for clonogenic survival of cell lines 
derived from the oral cavity and larynx. UMSCC-1 or UMSCC-11B cells were 
transiently transfected with either control siRNA or two different DHODH siRNAs. 
Colonies were grown for ~ 7 days, stained with crystal violet and counted using an 
automated colony counter. The images represent colony formation assay of indicated 
cell lines. The graph represents surviving fraction of cells in the colony formation 
assay. Blots represent knockdown efficiency of siRNAs. All experiments were 




5.4. DHODH expression is critical for the clonogenic survival of cell lines 
derived from oropharynx and hypopharynx  
Similarly, we examined the importance of DHODH for cell survival in other cancer 
cell lines by transiently transfecting cells, derived from oropharynx and hypopharynx, 
with either control siRNA or two different DHODH siRNAs and performing 
clonogenic assay. The results of this assay revealed that the colony numbers and sizes 
were largely reduced upon silencing of DHODH (Figure 5.5), suggesting that DHODH 
expression is essential for clonogenic survival in these cancer cells.      
   
                                                          
                             
Figure 5.5. DHODH expression is critical for clonogenic survival of cell lines 
derived from the oropharnx and hypopharaynx. UMSCC-81B or FaDu cells were 
transiently transfected with either control siRNA or two different DHODH siRNAs. 
Colonies were grown for ~ 7 days, stained with crystal violet and counted using an 
automated colony counter. The images represent colony formation assay of indicated 
cell lines. The graph represents surviving fraction of cells in the colony formation 
assay. Blots represent knockdown efficiency of siRNAs. All experiments were 




5.5. Teriflunomide significantly reduces clonogenic survival of cell lines 
derived from oral cavity and larynx  
To assess if chemical inhibition of DHODH alters cell survival, cell lines derived 
from oral cavity and larynx were exposed to teriflunomide (10  and 20 ) and 
clonogenic assay was performed. The results of this assay revealed that the colony 
numbers and sizes were largely reduced in a concentration dependent manner (Figure 
5.6), suggesting that chemical inhibition of DHODH alters clonogenic survival in these 
cancer cells.         
  
                           
                                                       
Figure 5.6. Teriflunomide reduces clonogenic survival of cell lines derived from 
the oral cavity and larynx. UMSCC-1 or UMSCC-11B cells were exposed to 
teriflunomide (10  and 20 ). Colonies were grown for ~ 7 days, stained with 
crystal violet and counted using an automated colony counter. The images represent 
colony formation assay of indicated cell lines. The graph represents surviving fraction 
of cells in the colony formation assay. All experiments were independently performed 
three times. Error bars = Mean ± SEM. ** p ≤ 0.005, *** p ≤ 0.001.                                           
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5.6. Teriflunomide significantly reduces clonogenic survival of cell lines 
derived from oropharynx and hypopharynx 
Similarly, the effect of teriflunomide was examined in other cancer cell lines 
derived from oropharynx and hypopharynx. Cells were exposed to teriflunomide (10 
 and 20 ) and clonogenic assay was performed. The results of this assay 
revealed that the colony numbers and sizes were largely reduced upon teriflunomide 
exposure in oropharynx cells, but it does not affect the clonogenic survival of FaDu 
cells (Figure 5.7), suggesting that the chemical inhibition of DHODH exerts its effect 
only in oropharynx cancer cells. 
                             
                                                       
Figure 5.7. Teriflunomide exhibits varying effects on clonogenic survival of cell 
lines derived from the oropharnx and hypopharaynx. UMSCC-81B or FaDu cells 
were exposed to teriflunomide (10  and 20 ). Colonies were grown for ~ 7 days, 
stained with crystal violet and counted using an automated colony counter. The images 
represent colony formation assay of indicated cell lines. The graph represents 
surviving fraction of cells in the colony formation assay. All experiments were 




5.7. Teriflunomide significantly reduces FaDu clonogenic survival  
To assess the clonogenic survival ability of FaDu with teriflunomide. Cells were 
exposed to increasing concentrations of teriflunomide and clonogenic assay was 
performed. The results of this assay revealed that the FaDu clonogenic survival ability 
was reduced in a concentration dependent manner (Figure 5.8), suggesting that the 
FaDu cells needs higher concentration of teriflunomide. It has been reported that FaDu 
cells inherently associated with multi drug resistance221, this could be the one of the 
reasons hypopharyngeal cancer difficult to treat with conventional chemotherapeutic 
agents. Further studies need to conduct to understand FaDu cells mediated multidrug 
resistance role in chemotherapy. However, given the absence of data on primary cells/ 




Figure 5.8. Teriflunomide reduces FaDu clonogenic survival in a concentration-
deoendent manner. FaDu cells were exposed to indicated concentration of 
teriflunomide. Colonies were grown for ~ 7 days, stained with crystal violet and 
counted using an automated colony counter. The images represent colony formation 










5.8. Orotate supplementation rescues teriflunomide-mediated clonogenic cell 
survival in most HNSCC cell lines.   
Since genetic and chemical inhibition of DHODH significantly alters clonogenic 
survival ability in several HNSCC, pyrimidine metabolism may be regulating 
teriflunomide-mediated cell death. It has been reported that orotate is the product of 
DHODH and orotate is further converted to uridine in the presence of UMP 
synthetase126. Hence it is possible that exogeneous metabolic supplementation of 
orotate and uridine may alter teriflunomide-mediated cell death. To assess if metabolic 
supplementation of orotate alters teriflunomide-mediated cell death in cell lines 
derived from oral cavity and larynx, cells were exposed to orotate (500 µM) and 
teriflunomide (20 ) and then clonogenic assay was performed. The results of this 
assay revealed that teriflunomide-mediated decrease in colony counts was greatly 
reversed upon exogeneous supplementation of orotate (Figure 5.9), suggesting that 
orotate alters teriflunomide-mediated reduction in clonogenicity. Similarly, the effect 
of orotate in teriflunomide-mediated clonogenic cell death was examined in other cell 
lines derived from oropharynx and hypopharynx. Cells were exposed to orotate (500 
µM) and teriflunomide (20 ) then clonogenic assay was performed. The results of 
this assay revealed that the colony numbers and sizes were largely reduced upon 
teriflunomide exposure in oropharynx cells, but it does not affect the clonogenic 
survival of FaDu cells. In agreement with the findings from UM-SCC-1 and UM-SCC-
11B, orotate supplementation reversed the effect of teriflunomide in UM-SCC-81B 
(Figure 5.9). 
 
5.9. Uridine supplementation rescued teriflunomide-mediated clonogenic cell 
survival in most cell lines.   
Similar to the above experiments, metabolic supplementation of uridine (500 
µM) reversed the effect of teriflunomide on UM-SCC-1, UM-SCC-11B (Figure 5.11) 
and UM-SCC-81B (Figure 5.12) cells. However, rescue following orotate or uridine 
could not be observed in FaDu cells, as at concentrations tested (20 µM), teriflunomide 





                                          
Figure 5.9. Orotate supplementation rescues the effect of teriflunomide in cell 
lines derived from the oral cavity and larynx. UMSCC- 1 or UMSCC-11B cells 
were pre-exposed to orotate (500 ) and then exposed to teriflunomide (20 ). 
Colonies were grown for ~ 7 days, stained with crystal violet and counted using an 
automated colony counter. a) The images represent colony formation assay of 
indicated cell lines. b) The graph represents surviving fraction of cells in the colony 
formation assay. All experiments were independently performed three times. Error 







                                
Figure 5.10. Orotate supplementation rescues the effect of teriflunomide in cell 
lines derived from the oropharnx and hypopharaynx. UMSCC-81B or FaDu cells 
were pre-exposed to orotate (500 ) and then exposed to teriflunomide (20 ). 
Colonies were grown for ~ 7 days, stained with crystal violet and counted using an 
automated colony counter. a) The images represent colony formation assay of 
indicated cell lines. b) The graph represents surviving fraction of cells in the colony 
formation assay. All experiments were independently performed three times. Error 







                                            
Figure 5.11. Uridine supplementation rescues the effect of teriflunomide in cell 
lines derived from the oral cavity and larynx. UMSCC- 1 or UMSCC-11B cells 
were pre-exposed to uridine (500 ) and then exposed to teriflunomide (20 ). 
Colonies were grown for ~ 7 days, stained with crystal violet and counted using an 
automated colony counter. a) The images represent colony formation assay of 
indicated cell lines. b) The graph represents surviving fraction of cells in the colony 
formation assay. All experiments were independently performed three times. Error 






                                              
Figure 5.12. Uridine supplementation rescues the effect of teriflunomide in cell 
lines derived from the oropharnx and hypopharaynx. UMSCC-81B or FaDu cells 
were pre-exposed to uridine (500 ) and then exposed to teriflunomide (20 ). 
Colonies were grown for ~ 7 days, stained with crystal violet and counted using an 
automated colony counter. a) The images represent colony formation assay of 
indicated cell lines. b) The graph represents surviving fraction of cells in the colony 
formation assay. All experiments were independently performed three times. Error 
bars = Mean ± SEM. *** p ≤ 0.001. 
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5.10. Teriflunomide does not synergise with cisplatin in reducing the 
clonogenic survival of all HNSCC cell lines 
To assess if teriflunomide synergise with cisplatin in the different HNSCC cell 
lines, cells were exposed to cisplatin (0.5 µM) and teriflunomide (10 µm and 20 µM) 
and clonogenic assay was performed. Concentrations of cisplatin were calculated 
based on IC50 measurements, carried out by exposing all the cell lines to increasing 
concentrations of cisplatin. This data is not shown in this thesis, as this was performed 
by other members in the Varadarajan lab. All HNSCC cell lines used in this study were 
sensitive to cisplatin at higher concentrations (1 µM), and therefore, a concentration 
of 0.5 µM was chosen to ensure that there will be some effect on clonogenicity, which 
could potentially show synergy with simultaneous exposure to DHODH inhibitors. 
The results of this assay revealed that the colony numbers and sizes were largely 
reduced upon increasing concentrations of teriflunomide. However, there was no 
enhanced reduction in the number of colonies when both cisplatin and teriflunomide 
were administered together (Figures 5.13 and 5.14).  
 
5.11. Teriflunomide does not synergises with A-1331852 in cell lines derived 
from oral cavity and larynx.  
To assess if teriflunomide synergises with A-1331852 in cell lines derived from 
oral cavity and larynx. Cells were exposed to A-1331852 (0.1 µM) and teriflunomide 
(10 µm and 20 µM) then clonogenic assay was performed. The results of this assay 
revealed that the colony numbers and sizes were largely reduced upon teriflunomide 
exposure in oral cavity and larynx cells which was not synergised with A-1331852 
(Figure 5.15). Suggesting that teriflunomide combination may not require for A-
1331852 synergy in these cells. Similarly, the effect of teriflunomide synergy with A-
1331852 was examined in other cell lines derived from oropharynx and hypopharynx. 
Cells were exposed to A-1331852 (0.1 µM) and teriflunomide (10 µm and 20 µM) 
then clonogenic assay was performed. The results of this assay revealed that the colony 
numbers and sizes were largely reduced upon teriflunomide exposure in oropharynx 
cells, but it does not affect the clonogenic survival of FaDu cells. A-1331852 did not 




                            
                                                                
 
                          
                                                                   
                           
                   
Figure 5.13. Teriflunomide does not synergise with cisplatin in cell lines derived 
from the oral cavity and larynx. UMSCC- 1 or UMSCC-11, cells were pre-exposed 
to cisplatin (0.5 ) and then teriflunomide (10  and 20 ). Colonies grown for 
~ 7 days, stained with crystal violet and counted using an automated colony counter. 
a) The images represent colony formation assay of indicated cell lines. b) The graph 
represents surviving fraction of cells in the colony formation assay. All experiments 
were independently performed three times. Error bars = Mean ± SEM. ** p ≤ 0.005, 






                                                                      
     
   
                                                                       
                    
                 
Figure 5.14. Teriflunomide does not synergise with cisplatin in cell lines derived 
from the oropharnx and hypopharaynx. UMSCC-81B or FaDu, cells were pre-
exposed to cisplatin (0.5 ) then teriflunomide (10  and 20 ). Colonies were 
grown for ~ 7 days, stained with crystal violet and counted using an automated colony 
counter. a) The images represent colony formation assay of indicated cell lines. b) The 
graph represents surviving fraction of cells in the colony formation assay. All 
experiments were independently performed three times. Error bars = Mean ± SEM. ** 






                            
                                                                
   
                          
                                                                   
                           
                             
Figure 5.15. Teriflunomide does not synergise with A-1331852 in cell lines derived 
from the oral cavity and larynx. UMSCC- 1 or UMSCC-11B, cells were pre-exposed 
to 1331852 (0.1 ) and then teriflunomide (10  and 20 ). Colonies were 
grown for ~ 7 days, stained with crystal violet and counted using an automated colony 
counter. a) The images represent colony formation assay of indicated cell lines. b) The 
graph represents surviving fraction of cells in the colony formation assay. All 
experiments were independently performed three times. Error bars = Mean ± SEM. ** 







                                                                      
   
   
                                                                       
 
                                
Figure 5.16. Teriflunomide does not synergise with A-1331852 in cell lines derived 
from the oropharnx and hypopharaynx. UMSCC-81B or FaDu, cells were pre-
exposed to 1331852 (0.1 ) and then teriflunomide (10  and 20 ). Colonies 
were grown for ~ 7 days, stained with crystal violet and counted using an automated 
colony counter. a) The images represent colony formation assay of indicated cell lines. 
b) The graph represents surviving fraction of cells in the colony formation assay. All 
experiments were independently performed three times. Error bars = Mean ± SEM. ** 







5.12. Teriflunomide does not synergises with S63845 in cell lines derived from 
oral cavity and larynx  
To assess if teriflunomide synergises with S63845 in cell lines derived from oral 
cavity and larynx. Cells were exposed to S63845 (0.1 µM) and teriflunomide (10 µm 
and 20 µM) then clonogenic assay was performed. The results of this assay revealed 
that the colony numbers and sizes were largely reduced upon teriflunomide exposure 
in oral cavity and larynx cells which was not synergised with S63845 (Figure 5.17), 
suggesting that teriflunomide combination may not require for S63845 synergy.  
Similarly, the effect of teriflunomide synergy with S63845 was examined in 
other cell lines derived from oropharynx and hypopharynx. Cells were exposed to 
S63845 (0.1 µM) and teriflunomide (10 µm and 20 µM) then clonogenic assay was 
performed. The results of this assay revealed that the colony numbers and sizes were 
largely reduced upon teriflunomide exposure in oropharynx cells, but it does not affect 
the clonogenic survival of FaDu cells. S63845 does not show any synergy with 



















                            
                                                                
 
 
                          
                                                                   
 
              
 
 Figure 5.17. Teriflunomide does not synergise with S63845 in cell lines derived 
from the oral cavity and larynx. UMSCC-1 or UMSCC-11B, cells were pre-exposed 
to S63845 (0.1 ) and then teriflunomide (10  and 20 ). Colonies grown for 
~ 7 days, stained with crystal violet and counted using an automated colony counter. 
a) The images represent colony formation assay of indicated cell lines. b) The graph 
represents surviving fraction of cells in the colony formation assay. All experiments 
were independently performed three times. Error bars = Mean ± SEM. ** p ≤ 0.005, 





                                                                      
   
 
  
                                                                       
 
                     
 
Figure 5.18. Teriflunomide does not synergise with S63845 in cell lines derived 
from the oropharnx and hypopharaynx. UMSCC-81B or FaDu, cells were pre-
exposed to S63845 (0.1 ) and then teriflunomide (10  and 20 ). Colonies 
were grown for ~ 7 days, stained with crystal violet and counted using an automated 
colony counter. a) The images represent colony formation assay of indicated cell lines. 
b) The graph represents surviving fraction of cells in the colony formation assay. All 
experiments were independently performed three times. Error bars = Mean ± SEM. ** 





5.13. Discussion  
Results from the previous chapter (Chapter 4) suggested that DHODH inhibitors 
played a critical role in ERMR-mediated apoptosis. Growing evidence suggests that 
DHODH acts as a candidate for several cancers, including AML128,147 . However, the 
effect of DHODH is still not well understood in HNSCC, which is one of the most 
common cancer-type worldwide217. Therefore, a more in-depth understanding of the 
role of DHODH will be useful to improve therapy in HNSCC.  
In this chapter, expression levels of DHODH in different HNSCC cell lines were 
examined. Western blot results showed that several HNSCC cells expressed high 
levels of DHODH (Figure 5.2). In addition to the 40 kDa band of DHODH that was 
detected in all cell lines, another band around 38 kDa corresponding to DHODH could 
be identified in UMSCC-11B and UMSCC-81B, suggesting the presence of multiple 
isoforms of DHODH in these cell lines. It has been reported that human DHODH 
exists as two isoforms with molecular weights of 40 kDa and 100 kDa. The additional 
band at 38 kDa could potentially due to alternative splicing of DHODH. Since HNSCC 
cells had a high expression of DHODH, it was further examined to assess the 
requirement of DHODH for cell survival. Upon DHODH silencing, HNSCC 
clonogenic survival was largely reduced (Figure 5.4-5.5). Similarly, chemical 
inhibition of DHODH also reduced clonogenicity in most of HNSCC cells (Figure 5.6-
5.7), suggesting that DHODH is critical for HNSCC survival. This could be due to a 
reduction in de novo pyrimidine biosynthesis or altered pro survival machinery.  
Subsequent results suggested that teriflunomide-mediated reduction in clonogenic 
survival was rescued with metabolic supplementation of pyrimidine (Figure 5.9-5.11), 
suggesting that DHODH inhibition alters pyrimidine pool and upon supplementation 
with orotate or uridine (key products of the DHODH reaction), cells regain adequate  
pyrimidine levels for maintaining cell survival homeostasis. Depletion of pyrimidine 
levels could cause cell cycle arrest which consequently can induce apoptosis. 
Together, these results suggested that teriflunomide-mediated reduction in cell 
survival is downstream of pyrimidine synthesis.  
Since currently available chemotherapeutic agents are not effective against 
HNSCC, teriflunomide could be combined with these drugs to improve therapy. 
Cisplatin is the one of the widely used chemotherapeutic agent for HNSCC treatment. 
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It kills cancer cell by damaging DNA and inhibiting DNA synthesis222–226. Cisplatin 
has not been effective in treating HNSCC due to problems arising from toxicity and 
drug resistance227. It is possible that cisplatin combination with teriflunomide may 
sensitise chemo-resistant cancer cells to undergo apoptosis with less toxicity to 
surrounding tissues. However, the combination of teriflunomide with cisplatin does 
not alter cell survival (Figures 5.13 and 5.14), as lower concentrations of cisplatin (< 
0.1 µM) was not effective on its own or in combination with teriflunomide. In contrast, 
higher concentrations of cisplatin (> 0.1 µM) was toxic to the cells even when used to 
single agents.  
It has been reported that BCL-XL and MCL-1 are highly expressed in 
HNSCC102,228–232. These anti-apoptotic proteins might be playing critical role in 
teriflunomide-mediated reduction in cell survival. Therefore, cells were exposed to 
combination of BCL XL inhibitor (A-1331852) and teriflunomide. However, this 
combination did not alter cell survival (Figure 5.15- 5.16), suggesting that BCL XL is 
not a key regulator for teriflunomide-mediated reduction in cell survival. Similarly, a 
combination of teriflunomide and MCL-1 inhibitor (S63845) also did not affect the 
reduction in clonogenic survival (Figure 5.17-5.18), suggested that MCL-1 also may 
not be the key regulator for teriflunomide-mediated reduction in cell survival. In 
summary, the present study showed that DHODH played an important role in HNSCC 
cell survival. However, further studies are required to confirm this observation in 




















ER-mitochondrial contacts play essential roles in regulating several cellular 
processes, including calcium regulation, lipid homeostasis, cell death and cell survival 
21,33,47,60,233. The functions of ER-mitochondrial contacts have been well characterised 
in calcium regulation and lipid biosynthesis33. However, the exact role of ER-
mitochondrial communication in apoptosis is still poorly understood. Understanding 
the intricacies of the apoptosis pathways in cancer is very important, as most of the 
cancer chemotherapeutic drugs have been designed to target the apoptosis pathway.  
In addition, the current challenge facing cancer therapy is drug resistance. Cancer cells 
have been reported to acquire resistance to chemotherapeutic drugs through different 
mechanisms, which include a failure to undergo apoptosis. This study is aimed at 
understanding the functional consequences of ER-mitochondrial communication in 
apoptosis by using ERMR as a tool.  
ERMR is a novel cellular stress response characterised by reversible 
reorganisation of ER membranes, following exposure of cells to a wide variety of 
drugs, such as apogossypol, ivermectin, terfenadine, suloctidil and other agents90,91. 
ERMR is evolutionary conserved from yeast to humans91. In addition, downregulation 
of anterograde transport protein (αSNAP), retrograde transport protein (syntaxin 18), 
anti-apoptotic protein (MCL-1) and upregulation of SOCE protein (STIM 1) also 
resulted in ERMR90,91. STIM1 is an ER resident calcium sensor that plays a critical 
role in SOCE90.  As STIM 1 is associated with calcium regulation, it is speculated that 
calcium regulation may essential for ERMR90.  It has been reported that 
downregulation of critical calcium regulated SOCE genes, such as STIM1, ORAI1 and 
ORAI3 had no effect on ERMR90. These results suggest that STIM1 may have other 
functions distinct from calcium regulation. Since ERMR is associated with diverse and 
specialised functions, including vesicular trafficking defects, mitochondrial fission 
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and apoptosis, it will be interesting to assess whether downregulation of αSNAP, 
syntaxin 18 and MCL-1 or an upregulation of STIM 1 would influence mitochondrial 
fission, MOMP and apoptosis.  
In this study, apogossypol is used as a prototype tool to understand functional 
consequences of ER-mitochondrial communication in apoptosis. Previous studies 
report that apogossypol regulates ERMR through ionic flux especially, influx of 
extracellular sodium ions but not calcium ionic flux90. Furthermore, apogossypol-
induced ERMR modulates ER associated functions, such as the vesicular trafficking 
between ER exit sites and the Golgi complex91. A drastic attenuation of  global protein 
synthesis has also been associated with ERMR91. Although these events result in a 
stress response, ERMR appears to be distinct from classical ER stress pathway and the 
unfolded protein response (UPR). ERMR occurs even in the absence of transcription 
and translation and also in cells lacking UPR regulators, such as PERK, IRE1, ATF6, 
XBP1 and CHOP91, suggesting that ERMR acts either upstream or independent of 
UPR. 
ERMR is a completely different process from other ER structural alterations, 
such as such as ER expansion, ER swelling, and ER whorls, which have been reported 
in the literature91. ER expansion has been observed during differentiation of B 
lymphocytes into plasma cells234. During this, ER membranes expand to more than 
three-fold of their original ER volume, and this expansion has been observed to 
provide massive space for B-cell differentiation234. In contrast, ER swelling is often 
associated with classical ER stress and the UPR235.  During UPR, large amounts of 
misfolded proteins accumulate inside ER lumen235. In order to handle such 
overwhelming accumulation of misfolded proteins, ER lumen often swells to provide 
the physical space required for protein folding processes, all of which relieves the 
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extent of ER stress235. ER whorls are identified during ER-phagy, during which 
severely damaged ER membranes are often eliminated through ER-selective 
autophagy236. During this phenomena, large clusters of damaged ER tubules wrap 
around one another in a circular pattern, which are recognised by the autophagosomes 
and eventually fuses with lysosomes to digest damaged ER236. ERMR noted in this 
study involves the reversible reorganisation of ER tubules and lack features that 
resemble ER expansion, ER swelling and ER whorls90,91. 
ER-mitochondrial contacts also play essential roles in mitochondrial fission237–
240. Growing reports suggest that mitochondrial fission is mediated by a series of 
events, which begin by the wrapping of ER tubules around mitochondria to mark 
mitochondrial constriction sites2,48,239,241. This later facilitates the recruitment of DRP-
1 to the fission site, where DRP-1 binds to its receptors such as MFF, MID49, MID51 
– all of which result in mitochondrial fission31,48,195,242. DRP-1 has been shown to 
undergo several post-translational modifications, including phosphorylation, which 
play regulatory roles in mitochondrial fission48,243. Data from this thesis indicates that 
ERMR prevents DRP-1-mediated mitochondrial fission, most likely by decreasing the 
phosphorylation status of DRP-1 (at S616, which is associated with mitochondrial 
fission)193,194. This is particularly interesting as similar observations have also been 
made in dengue virus infected cells244. Dengue virus often induces ERMR for 
replication and survival process244. It has been reported that in these cells, viral 
infection-induced ERMR prevented mitochondrial fission by decreasing the 
phosphorylation of DRP-1 at Ser 616 to favour viral replication244. These results 
suggested that there could be a strong link between ERMR and phosphorylation, which 
may affect its translocation from cytosol to mitochondria211. The effect of ERMR to 
prevent mitochondrial fission might be due to the inability of DRP-1 to translocate to 
127 
 
the mitochondrial membranes and this is evidenced by the trapped DRP-1 within the 
reorganised ER membranes (Figure 3.12). Recent studies suggest that DRP-1 
undergoes several post-translational including SUMOylation, which play critical role 
in DRP-1 stabilisation at mitochondrial fission site241. This involves the addition of 
SUMOs (small ubiquitin-like modifiers) to lysine residues in the target protein. The 
major key protein involved in SUMOylation of DRP-1 is MAPL241. It is a one of the 
SUMO E3 ligase family proteins, which play an active role in mitochondrial fission241.  
Mitochondrial fission occurs upstream of apoptosis, but the specific 
mechanisms remain poorly understood. Several sequential events, such as the 
recruitment of DRP-1 to mitochondrial fission site, BAX and BAK pore formation at 
OMM, mitochondrial cristae remodelling that is accompanied by OPA1 proteolysis, 
the release of cytochrome c from IMM to cytosol, and finally the caspase activation 
cascade,  form the distinct stages of the intrinsic apoptotic pathway101. OPA1 
proteolysis is regulated by YME1L (ATP dependent metalloprotease) and OMA1(zinc 
endopeptidase), which are responsible for cleaving OPA1 into L-OPA1 and S-
OPA1242,243,245. Upon OPA1 cleavage, cytochrome c trapped within the mitochondrial 
cristae releases into the cytosol through BAX and BAK pores in the OMM48,95,243. Data 
from this thesis suggests that ERMR prevented DRP-1-mediated mitochondrial 
fission, as well as BH3 mimetic-mediated BAX translocation, cytochrome c release 
and apoptosis (Figures 3.13-3.16). These results clearly suggest that ER tubules play 
essential roles in regulating BH3-mimetic-mediated apoptosis, by regulating 
mitochondrial fission.  Since ERMR prevented mitochondrial-mediated apoptosis, it 
may be possible that ERMR may also alter other ER functions, such as structural lipid 




Findings from this thesis revealed that DHODH inhibitors, including 
teriflunomide and leflunomide, prevented ERMR without perturbing normal ER 
morphology (Figure 4.4-4.5). More specific inhibitors of DHODH have been 
identified recently such as BAY2402234 and ASLAN003129,138. It will be interesting 
to assess whether these compounds also could prevent ERMR. DHODH inhibitors 
exhibit dual functions, inhibiting SOCE to prevent extracellular calcium influx into 
ER lumen, while also inhibiting the enzymatic activity of DHODH to diminish the 
pyrimidine pool203. This suggests that either SOCE-mediated calcium regulation or 
DHODH enzymatic activity may be regulating ERMR. It has been reported that down 
regulation of critical SOCE genes such as STIM1, ORAI1 and ORAI3 had no effect 
on ERMR90, suggesting that SOCE and its associated calcium regulation had no 
possible role in ERMR regulation. Findings from this study, involving a genetic 
knockdown of DHODH demonstrate that DHODH does not regulate ERMR (Figure 
4.9). However, it is very hard to rule out an involvement of DHODH in ERMR 
regulation at this moment, as the siRNAs used in this study failed to completely 
knockdown DHODH expression (Figure 4.9). Therefore, a complete knockout system, 
possibly achieved via CRISPR, may be necessary to understand the possible role of 
DHODH in regulating ERMR. However, metabolic supplementation of pyrimidine 
intermediates, such as orotate and uridine, also failed to alter ERMR, suggesting that 
a lack of pyrimidine synthesis was not critical for the regulation of ERMR. 
High levels of DHODH are observed in a wide range of HNSCC cell lines 
derived from oral cavity, larynx, oropharynx and hypopharynx (Figure 5.3). In 
addition, downregulation of DHODH decreases the clonogenic survival of all HNSCC 
cell lines, suggesting that DHODH might have critical role in HNSCC pathogenesis 
(Figure 5.3). These results were largely reproducible with DHODH inhibitors in all 
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HNSCC cell lines, except hypopharyngeal cells, which required a much higher 
concentration of teriflunomide (> 100µM). This is not surprising as most 
hypopharyngeal cells have been shown to inherently possess multi drug resistance221 . 
This partly explains why hypopharyngeal cells are hard to treat with chemotherapeutic 
drugs. Metabolic supplementation of orotate and uridine rescued teriflunomide-
mediated clonogenic survival in most HNSCC (Figure 5.9- 5.11), suggesting that 
orotate and uridine play important roles in regulating clonogenic cell survival. In 
addition to synthesising pyrimidines for nucleotide biosynthesis, pyrimidine 
metabolism also results in other end products, such as phosphatidylcholine (PC) and 
phosphatidylserine (PS)132. Further understanding of how PC and PS regulate cell 
death may give more information towards improving cancer therapy using DHODH 
inhibitors. 
Despite these observations, several important questions remain unanswered. In 
particular, how is DRP-1 trapped within ERMR? In other words, is there a well-
defined molecular machinery that directs DRP-1 to be trapped within ERMR? If 
ERMR affects BAX translocation and activation but not BAK activation, why is that 
enough to prevent BH3 mimetic-mediated apoptosis? Can active BAK not induce 
apoptosis in the absence of BAX? What is the role of other pro-apoptotic proteins in 
these processes? Further understanding of these points may unveil precise molecular 
events involving ER-mitochondrial contacts and apoptosis. Collectively, this 
information will widen our understanding of the ER-mitochondrial communication in 






The major findings presented this study are:  
• ERMR is restricted to ER tubules 
• ERMR does not form in other subcellular organelles  
• ERMR prevents DRP-1 mediated mitochondrial fission 
• ERMR prevents BH3 mimetic-mediated apoptosis 
• ERMR-mediated anti-apoptotic effects can be reversed by DHODH inhibitors 
• HNSCC cells express high levels of DHODH  
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